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Human immunodeficiency virus (HIV) infection is the leading cause of death globally. This dissertation 
addresses two HIV-1 target proteins namely, HIV-1 Reverse Transcriptase (RT) and Heat shock protein 
(Hsp) 90. More specifically for HIV-1 RT, a case study for the identification of potential inhibitors as 
anti-HIV agents was carried out. A more refined virtual screening (VS) approach was implemented, 
which was an improvement on work previously published by our group- “target-bound pharmacophore 
modeling approach”. This study generated a pharmacophore library based only on highly contributing 
amino acid residues (HCAAR), instead of arbitrary pharmacophores, most commonly used in the 
conventional approaches in literature. HCAAR were distinguished based on free binding energy (FBE) 
contributions, obtained using calculation from molecular dynamics (MD) simulations. Previous 
approaches have relied on the docking score (DS) to generate energy-based pharmacophore models.  
However, DS are reportedly unreliable. Thus we present a model for a per-residue energy decomposition 
(PRED), constructed from MD simulation ensembles generating a more trustworthy pharmacophore 
model which can be applied in drug discovery workflow. This approach was employed in screening for 
potential HIV-1 RT inhibitors using the pharmacophoric features of the compound GSK952. The 
complex was subjected to docking and thereafter MD simulations confirmed the stability of the system. 
Experimentally determined inhibitors with known HIV-RT inhibitory activity were used to validate the 
proposed protocol. Two potential hits ZINC46849657 and ZINC54359621 showed a significant 
potential with regards to FBE. Reported results obtained from this work confirm that this new approach is 
favourable to the future of drug design process.  
Hsp90 was recently discovered to play a vital role in HIV-1 replication. Thus has emerged, as a promising 
target for anti-HIV-1 drugs. The molecular mechanism of Hsp90 is poorly understood, thus the second 
study was aimed to address this issue and provide a clear insight to the inhibition mechanism of Hsp90. 
Reasonable continuous MD simulations were employed for both unbound and bound Hsp90 
conformations, to understand the dimerization and inhibition mechanisms. Results demonstrated that 




to a significant separation between orthogonally opposed residues, such as Arg591.B, Lys594.A, 
Ser663.A, Thr653.B, Ala665.A, Thr649.B, Leu646.B and Asn669A. A Large difference in magnitudes 
was observed in the radius of gyration (Rg), per-residue fluctuation, root-mean-square deviation (RMSD) 
and root-mean-square fluctuation (RMSF) confirming a completely more flexible state for the unbound 
conformation associated with dimerization. Whereas, a less globally correlated motion in the case of the 
bound conformer of Hsp90 approved a reduction of the dimeric process. This undoubtedly underlines the 
inhibition process due to ligand binding. The detailed dynamic analyses of Hsp90 presented herein are 
believed to give a greater insight and understanding to the function and mechanisms of inhibition of 
Hsp90. The report on the inhibitor-binding mode would also be of great assistance in the design of 
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1.1. Background and rationale for this study  
In this chapter, the background, rationale and novelty of this research project, which is associated to HIV-
1 infection, is clearly and precisely conferred. Acquired Immune Deficiency Syndrome (AIDS) is an 
advancement of Human Immunodeficiency Virus (HIV) infection1 and HIV is one of the leading cause of 
death globally2. Over 35 million people are affected with HIV/AIDS, of that, Sub-Saharan Africa being 
the most affected3 with approximately 5.7 million are in South Africa3. Factors contributing to this high 
number is poverty, inequality and social instability, high levels of sexually transmitted infections, sexual 
violence, high mobility and limited access to quality medical care4. Though research shows great levels in 
the understanding of HIV transmission and prevention methods, preventative behavior are still not 
practiced. The HIV pandemic in South Africa has induced an international response in the assistance of 
HIV research in both prevention and treatments5. 
Thus far, there is no cure for HIV/ADS due to high mutation rates6, which leads to drug resistance. 
Research has contributed much to improve current HIV treatment, which does not cure the virus but stops 
it from spreading and replicating7. A study by Ptak and collegues (2008) revealed  that there has been 
1448 human proteins identified that interact with HIV-1 involving 2589 distinctive HIV-1-to-human 
protein interactions8. There is currently more than twenty-five anti-HIV drugs which targets three known 
essential targets namely reverse transcriptase (RT), protease and intergrase (IN)9. These targets are crucial 
for different processes involved in HIV replication and survival. Reverse transcriptase consists of all vital 
enzymatic activity required for the conversion of HIV-1 single stranded RNA (ssRNA) into double 
stranded DNA (dsDNA) required for integration into the human genome10,11. Integrase enables the genetic 
material of the virus to be integrated into the DNA of an infected cell12. Protease is responsible for the 
maturation of the virus6,13. The anti-HIV drugs are divided into distinct classes namely nucleoside-analog 
RT inhibitors (NRTIs), non–nucleoside reverse transcriptase inhibitors (NNRTIs), Integrase inhibitors 
and Protease inhibitors (PIs)14. Reverse transcriptase is the target for more than half of the currently 
approved anti-AIDS drugs15. The efficacy of NNRTI drugs is reduced by the occurrence of drug-
resistance mutations16 due to the lack of exonucleolytic proofreading activity of  HIV-RT17 . As a results 
an abnormal strand is transferred into the DNA of the host cells18. Thus, the mutagenic virus replicate 





The use of computational tools have proved to be cost effective and less time consuming in the design and 
discovery of new drugs25. A number of studies have used computational tools such as molecular 
modelling, MD simulations, molecular docking, QSAR and virtual screening (VS) to improve existing 
drugs and to discover new RT inhibitor26–32. The use of VS has increased over the years in drug discovery 
industry33–36. A few studies have used phamarcophore models to identify novel and potent RT 
inhibitors37–39.  Herein, we used a new approach to screen for NNRTIs. This approach is aimed to improve 
the conventional methods of VS, which will aid the drug design workflow to design more potent RT 
inhibitors.  
Furthermore, Hsp90 has been recently reported as a potential target for HIV-140. Gyrase B inhibitors has 
been confirmed to impair viral gene expression by binding to Hsp9040,41. To understand the dimerization 
process and the inhibition of Hsp90 by C-A1, MD simulations were employed for both the apo and bound 
conformations. Post-dynamics analysis including RMSD, RMSF, Rg, PCA and DCCM were used to 
understand the structural fluctuations of both apo and bound conformations. The structural and dynamic 
insights presented herein, can be implemented in the drug discovery and development of more potent HIV 
inhibitors against Hsp90.  
In spite of the current treatment regimen, to date there is no cure or vaccination for HIV. Thus there is a 
great need for continued improvement on existing drugs as well as identification of novel and inhibitors.  
1.2. Aims and objectives of this study 
Broadly, the aims of this study were to investigate the inhibition of HIV-1 reverse transcriptase and the 
inhibition mechanism of Hsp90 by C-A1. These aims are further refined hereunder 
A. The aim of this work was to identify more potential NNRTIs by exploiting the structural features of 
GSK952 using a pharmacophore model approach. To accomplish this, the following specific objectives 
were outlined: 
1. Download the crystal structure from Protein Data Bank (PDB) website 
2. Prepare ligand and receptor from crystal structure 
3.  Run MD simulation  
4. Select paharmacophore moieties based on highly contributing residues 




6. Run molecular docking on above generated library 
7. Run MD simulation on top ranked hits 
8. Identify potential hits.   
B. The aim of this work was to investigate the inhibition mechanism of Hsp90, a potential HIV-1 target 
protein, by the Gyrase B inhibitor C-A1. To accomplish this, the following specific objectives were 
outlined: 
         1. Download the crystal structure of Hsp90 protein. 
 2. To draw C-A1 from the SMILES using the Avogadro software. 
 3. To prepare both Hsp90 and C-A1 on chimera. 
 4. To dock C-A1 against Hsp90 from the PDB repository.  
     5. To Run MD simulation on docked Hsp90- C-A1 complex. 
 6. To do post-analysis from MD simulation. 
1.3. Novelty and significance of this study 
HIV-1 reverse transcriptase (RT) inhibition is a key focus of current anti-HIV drug discovery42 as 17 of 
the 31 FDA-approved compounds target RT and it is a prominent target of many approved anti-HIV drugs 
that are key components of Highly Active Anti-Retroviral Therapies (HAART)43  
Several computational screening tools are available for the mining of inhibitors having properties of 
significance44. Virtual screening is one of the most trusted and convenient tools in drug design45. Its 
reliability in the discovery of novel HIV-1 RT inhibitors has been confirmed in literature45. Virtual 
screening can be either ligand-based or structure based46. Ligand-based VS (LBVS) also known as 
pharmacophore-based VS, uses favorably features or properties of known bioactive ligands to build  a 
pharmacophore model and searches for compounds with similar features47. Pharmacophore models is the 
best at discovering a range of chemical structures with possible features, thus the major method for the 
preliminary selection of compounds48. Ligand-based pharmacophore approaches generates libraries based 
on a set of known ligands illustrative of crucial interactions between the ligands and a particular target49. 
Whereas structure-based pharmacophore models are based on the knowledge of the 3D structure of the 
target50. A number of studies have combined LBVS and SBVS with the aim of improving the VS 




58. A previous study proposed a target-bound ensemble generated pharmacophore model to further 
improve the pharmacophore-based VS. It has been confirmed that a target-bound pharmacophore-based 
VS is a more rational approach59. Yet to date, general standards for VS with regards to method evaluation 
are insufficient. An approach implemented in this study, aimed to improve and refine the current 
pharmacophore approach. Our approach was centered on the type of molecular interactions such as 
hydrogen bonding, charge, and hydrophobic interactions60. This approach searched for compounds that 
interact with highly contributing residues based on the Free Binding Energy. This work identified more 
potential NNRTIs by exploiting the structural features of GSK952 using a pharmacophore model. 
Reported results obtained from this work see (chapter 4) confirm that the refinement of this approach is 
favorable to the future of drug design industry.  
Hsp90 has been recently reported as a potential target for anti-HIV drugs40. It has also been found that the 
CTD demonstrate favorable activities within the binding pocket61. Coumermycin A1 (C-A1), a very 
potent Gyrase B inhibitor, was reported to disrupt the HIV-1 replication by targeting Hsp90 
dimerization40. The understanding of the complex biological phenomena’s involved in this process 
deserves great attention; hence the confirmation of the impairment of viral gene expression by C-A1 
binding to Hsp90 is vital. This study validated these findings through computational methods. To the best 
of our knowledge this is the first report of the binding mechanism of C-A1 to Hsp90. The results reported 
for this study (see Chapter 5), which validates inhibition of viral gene expression, could also be 
implemented within the drug discovery industry to develop more potent HIV-1 inhibitors against Hsp90. 
1.4. Overview of this thesis 
This thesis has the total of six chapters, including this one: 
Chapter 2: This chapter outlines endemic and therapy of HIV/AIDS infection. A historical background 
on HIV/AIDS is provided at the beginning of this chapter proceeding to most current statistics on the 
number of HIV-infected people globally including African continents. Details of HIV/AIDS are also 
highlighted which includes HIV virus structure; life cycle and the fundamental enzymes required for HIV 
lifecycle and targets anti-HIV therapy.  The HIV-1 RT and Hsp90 enzymes are essential drug targets and 
are the principal focus of this work, which will be addressed in more detail. This will include the 
structure, inhibitor design strategies and the current FDA-approved inhibitors for each enzyme. 
Chapter 3: A general introduction to computational chemistry, different molecular modeling and 
simulation techniques and their applications are provided in this chapter. Theoretical descriptions for 
some of the computational methods have been explained where applicable. Several computational tools 




molecular mechanics, molecular docking and FBE calculations. Previous reports on computational studies 
on HIV-1 RT and reports on Hsp90 as potential HIV-1 target also formed part of this chapter.  
Chapter 4: Published work –This chapter presents the research paper titled “Per-residue energy 
decomposition (PRED) pharmacophore model to enhance virtual screening (VS) in drug discovery: A 
case study for identification of Reverse transcriptase (RT) inhibitors as potential Anti-HIV agents.” and it 
was accepted in the Dove Medical Press journal Objectives of this paper were addressed in 1.2.A 1, 2, 3, 
4, 5, 6, 7 and 8.  
Chapter 5: Submitted work – This chapter presents the final and revised version of the submitted 
research paper from this study. The title of the paper is “Gyrase inhibitor coumermycin A1 (C-A1) inhibit 
Hsp90 Dimerization: Insights from Molecular Dynamics.” Objectives of this paper were addressed in 1.2 
.B 1, 2, 3, 4, 5 and 6. Chapter 6: This chapter consists of the conclusion for the whole thesis and the 
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2. Background on HIV/AIDS 
 2.1. Introduction 
In this chapter a brief description on the background, life   cycle   and   treatment   of   Human 
Immunodeficiency Virus (HIV), the causative agent of Acquired Immunodeficiency Syndrome (AIDS) is 
provided. The main focus will be on HIV-1 RT and it inhibitors. A brief discussion on Hsp90 as potential 
HIV-1 target will be included.  
2.2. A brief history of HIV/AIDS 
Human Immunodeficiency Virus is believed to have originated from a type of chimpanzee in West 
Africa, which was infected by simian immunodeficiency virus (SIV)62. The earliest known case of 
infection with HIV-1 in a human was in 1959 from a man in the Democratic Republic of the Congo, 
which was detected in his blood sample63. Acquired Immune Deficiency Syndrome was first documented 
as a new disease in 198162 and confirmed to be originated from HIV later in 198364. There are two types 
of HIV, which are HIV-1 and HIV-265,66. The HIV-1 infection is more virulent than HIV-2 and it is 
predominant across the globe67. The leading mode of HIV transmission is heterosexual transmission, 
which accounts for approximately 85% of all HIV-1 infections68. A number of factors have contributed on 
promoting the incidence of HIV, which includes migration, urbanization and family disruption, economic 
underdevelopment and poverty69. 
The HIV pandemic has not only affected people’s health but also the economy growth. The economy has 
affected sectors such as the households, firms, health, transport, mining, education and water70,71. The 
global statistics by WHO reported that there were approximately 35 million people with HIV/AIDS 
infection all over the world, with Sub-Saharan Africa being the most affected region, with 24.7 million 
people living with HIV72. The current UNSAID statistic reported that there is a decrease in new HIV 
infection since 2001, decrease in AIDS related deaths since 2005 for both children and adults, a decrease 
in new HIV infections in children by 33%, 29% and 52% respectively73. South Africa has been recently 
reported to have the highest number of new HIV infections compared to the rest of the world74. 
2.3. Human immunodeficiency virus 
Human immunodeficiency virus is associated with a group of viruses known as retroviruses75. The HIV 
virus is a virus that weakens the immune system by infecting the immune system cells76. The proteins 




major genes, 5'gag-pol-env-3', encoding for key structural proteins, which includes the viral envelop 
(glycoprotein (gp) 120 and transmembrane gp41), the gag polyprotein such as gp17, the viral core capsule 
protein gp24, SP1 (spacer peptide 1, p2); NC (nucleocapsid protein, p7); SP2 (spacer peptide 2, p1) and 
P6 protein77.These major genes also encode essential enzymes, which include RT, IN, Ribonuclease and 
Protease77. There are also accessory proteins, which assist HIV virus for an efficacious infection, which 










2.4. The HIV-1 life cycle 
Viruses need to infect cells to reproduce81. Like any other viruses, HIV does the same to human immune 
system cells76. The HIV infection involves a number of events, which are illustrated in the life cycle in 
Figure 2.2 below. The HIV life cycle involves six stages known as binding and fusion, reverse 






Figure 2.2: Systematic presentation of HIV replication cycle adapted from 83. 
 
(i). Binding and fusion. 
The initial step for HIV-1 life cycle is the binding and fusion of the virus into the host cell i.e. the human 
immune system84. The HIV-1 virus uses CD4 antigen for it entry into the host cell84. Chemokine receptors 




membrane85. This is achieved by the binding of envelop glycoproteins gp120 to CCR5 and CXCR4, 
which causes conformational changes to both gp120 and gp41 thus membrane fusion reaction is triggered 
which brings the viral core into the cytoplasm of the host cell86. Research have identified these three 
stages of viral entry as targets for the development of anti-HIV therapy. These include gp120 inhibitors87–
92,  CCR5 inhibitors93,94, CXCR4 inhibitors95–99 and gp41 inhibitors100–105. 
(ii). Reverse transcription. 
The reverse transcription process begins as soon as the viral particle move into the cytoplasm of the target 
host10. Reverse transcriptase is responsible for the conversion of RNA into a double-stranded 
DNA43,106,107.   
(iii). Integration. 
The integration step occurs after RNA has been transcribed into a double stranded DNA. An enzyme 
called Integrase is required in this step to incorporate DNA copy (provirus) into the DNA of the host 
cell108.  This is achieved by the cleaving of the viral DNA at each of the 3′ end creating the precursor ends 
for integration109. The cleaved fragments of viral DNA are joint into the host’s DNA110. 
(iv). Transcription and translation. 
After the integration stage the provirus acts as a template for transcription which is controlled at the 
transcriptional and posttranscriptional levels111. The spliced messenger RNA (mRNA) are produced 
which encodes viral regulatory proteins Tat and Rev112. Furthermore, the regulatory protein Tat stimulates 
transcription and Rev suppresses splicing and assist in the transportation of unspliced viral mRNA to the 
cytoplasm113. The unspliced mRNA encoding the viral structural proteins are translated and assembled 
into virus particles114. 
(v). Assembly. 
The HIV genetic material gather together with new HIV proteins and enzymes to form new viral 
particle115. 




After the new viral particles have been assembled, they bud off the host cell, creating a new virus, which 
then matures and become infectious116. Each step of the HIV-1 cycle forms part of anti-HIV therapy and 
these are discussed further in the next sub-section.  
2.5. The HIV-1 virus infection current treatments.  
The fields of biology, pharmacology and clinical care have all greatly contributed in changing HIV 
infection from being a fatal illness to a chronic diseases that is manageable117. Combination of medicines 
are used in treating HIV infection118. The anti-HIV therapy does not cure HIV but controls the virus by 
decreasing the viral load in the blood119.  Azidothymidine (AZT) was the first anti-HIV drug approved in 
1987120. To date, 25 anti-HIV drugs have been approved121, which include Nucleoside and nucleotide 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
protease inhibitors (PI), integrase inhibitors and entry inhibitors122. Fusion inhibitors are also part of anti-
HIV drugs123 and enfuvirtide (T20), Fuzeon is the only approved fusion inhibitor by far124.  
2.5.1 Fusion/entry inhibitors 
The fusion of the HIV-1 virus is an early stage of the life cycle of HIV-1. To date there are two inhibitors 
inhibiting this stage namely T20  and Maraviroc (MVC) which were approved in 2003 and 2007 





Figure 2.3: FDA-approved fusion inhibitors 
There are other agents, which are still under investigation for their ability to interact with the proteins 
involved in HIV entry and their possibility to serve as entry inhibitors127. These include Fostemsavir, 





Figure 2.4: Agents under investigation as potential fusion inhibitors 
2.5.2 Reverse transcriptase inhibitors 
Reverse transcription is an essential step in the HIV-1 life cycle that involves the conversion of retroviral 
RNA to proviral DNA by the enzyme reverse transcriptase (RT)128. The two categories of RT inhibitors 
include NRTIs (Figure 2.5) and NNRTIs (Figure 2.6). The NRTIs binds to HIV-1 RT competitively, 
terminating the synthesis of proviral DNA129. Zidovudine is the first NRTI which was discovered in 
1985129. Later, more NRTI were discovered which include didanosine, zalcitabine stavudine, lamiduvine, 





Figure 2.5: FDA-approved NRTIs 
The NNRTIs were first reported between 1989 and 1990131. These inhibitors are said to inhibit HIV-1 RT 
in a non-competitive manner132. Nevirapine, Efarivenz and delavirdine are the first generation NNRTIs132. 
Etravirine is the second generation of NNRTIs133, which was first approved in 2008134 and Rilpivirine, 





Figure 2.6:  FDA-approved NNRTIs 
The integration of HIV-1 genetic material into the host cell genome is a required replication step of the 
HIV life cycle Integrase is thus an essential target for therapeutic intervention136. The first FDA-approved 
Integrase inhibitor is Raltegravir in 2007136,137  followed by Elvitegravir in 2012138 and dolutegravir in 
2013139 (Figure 2.7). 
 
Figure 2.7: FDA-approved Intergrase inhibitors 
2.5.4 Protease inhibitors 
The HIV-1 protease cut the longer viral polypeptide chain precursor into individual mature and functional 
viral proteins140. Protease inhibitors are potent antiretroviral drugs and represent a fundamental 
component of highly active antiretroviral therapy (HAART)141. Protease inhibitors bind competitively to 
protease’s active site142, preventing the virus from reaching it infectious stage of maturity143. The FDA 
approve the first PIs between 1995 and 1996144. There are eleven PIs (Figure 2.8) exit in the market to 
date, namely saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, fosamprenavir, atazanavir, 














2.6. The HIV-1 viral enzymes. 
2.6.1. HIV-1 RT enzyme 
A multifunctional enzyme, HIV-1 RT is responsible for copying the single-stranded viral RNA genome 
into double-stranded DNA146. The HIV-1 RT is one of the central targets in the anti-AIDS therapy147 and 
It is a heterodimer comprised of two subunits namely p56 and p66148. The p56 is a smaller subunit 
consisting of 440 amino acid and p66 is a longer subunit with 560 amino acid149. It is comprised of four 
subdomains namely “fingers ”,“palm ”,“thumb ”, and “connection ” by comparison to a human right 
hand146  illustrated in Figure 2.9.  
 
Figure 2.9: Ribbon representation of the HIV-1 RT-GSK952 complex (PDB code 2YNI150) with finger 
(blue), palm (magenta), thumb (cyan), connection (forest green) and RNase H (orange red) of p66 subunit 
and GSK952 (green). 
The HIV-1 RT has two enzymatic activities, a DNA polymerase which uses RNA template to make a 
DNA strand and RNase H that cleaves the RNA strand, (both in the p66 subunit), after the DNA strand 
has been built151. The HIV-1 RT uses transfer RNA (tRNA) to build cDNA from sRNA to form DNA-
RNA hybrid152 (Figure 2.10). The tRNA binding to the 3’ long terminal repeat, base paired to a 









Figure 2.10: Schematic diagram of cDNA synthesis during transcription adapted from 26. 
The RNase H degrades the 5′ end of the viral RNA, exposing the newly synthesized minus-strand 
DNA153. The two RNA fragments resistant to RNase H cleavage become templates for the synthesis of a 
plus-strand DNA154,155. A full-length double-stranded DNA copy is then produced by transfer step, which 
is incorporated into the host genome156.  
2.6.2. Heat shock protein (Hsp) 90.  
Hsp90 is the fundamental constituent of a complex chaperone system157. Hsp90 is a vastly abundant, 
ATP-dependent molecular chaperon essential for the activation and stabilization of a variety of client 
proteins involved in cellular processes such as cell survival, hormone and cellular pathways158,159. Hsp90 




It is a homodimer consisting of two important isoforms: the Hsp90α and Hsp90β162–165 entailing four 
domains166 namely N-terminal ATP-binding domain (NTD), middle domain (MD), and a C-terminal 
dimerization domain (CTD) and charged linker that connects the N-terminal and middle domains167–171, as 
illustrated in Figure 2.11. The NTD makes up the binding site of the nucleotide, MD is significant for the 
binding of several substrates and the CTD is primarily responsible for the dimerization of the protein168. 
Previous studies later discovered a second ATPase binding site in the CTD of Hsp90172. Chapter 5 entails 
an in-depth discussion about the Hsp90. 
 
Figure 2.11: The crystal structure of Hsp90α and Hsp90β (PDB code 2CG9) in light sea green and orange 
respectively 
Hsp90 was first and originally discovered for it potential as an anti-cancer drug target in the 1990’s173. 
This resulted in great efforts and enthusiasm from researchers to develop potential small molecule which 
are clinically viable as Hsp90 inhibitors174,175. There are currently no FDA approved Hsp90 inhibitors175. 
Previously reported Hsp90 inhibitors include geldanamycin antibiotic176, the first inhibitor to reach 




inhibit Hsp90 in 1998179. Novobiocin which inhibits the protein folding machinery of CTD of Hsp90 
responsible for the conformational maturity of various proteins involved in cancer growth and survival180. 
Coumermycin A1 (C-A1) is a DNA Gyrase B inhibitor181, which is naturally produced by Streptomyces 
rishiriensis182. The C-A1 binds to the N-terminal domain of Gyrase B DNA and inhibit the activity of it 
ATPase183. Recently C-A1 was reported as the inhibitor of Hsp90184. Another study confirmed that the C-
A1 inhibitor hinders the dimerization process situated at the CTD of Hsp90. The identification and 
characterization of Hsp90 structure and dynamics and it mechanism of inhibition, form the heart of this 
study and in hope it can be implemented in the drug discovery and development of more potent HIV 
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3. Introduction to computational chemistry and molecular modeling 
In this chapter, a broad-spectrum introduction to computational chemistry, different molecular modeling, 
simulation techniques and their uses are provided. Theoretical descriptions of the computational methods 
have been explained where applicable. A brief enlightenments of the various computational tools 
employed in HIV research with primary focus on molecular dynamics simulations, molecular mechanics, 
molecular docking, binding free energy calculations, pharmacophore model and virtual screening is also 
included.  
3.1. Introduction to Computational Chemistry  
Computational chemistry is a division of chemistry which uses computer as an experimental tool and is 
concentrated on obtaining results significant to chemical problems instead of directly emerging new 
theoretical methods185. The models used includes chem-informatics, molecular mechanics, semi-empirical 
methods and ab initio quantum chemistry which are dependent on experimental information such as 
parameters and energy levels186. Computer aided drug design (CADD), represents computational methods 
and resources that are used to enable the design and discovery of new therapeutic elucidations187, and 
computer-aided molecular design (CAMD), generates compounds with desired properties188, are methods 
which help escalate the effectiveness of the drug design process by using the available experimental 
data188,189, thus identifying lead compounds and predicting their side-effects.  
Molecular dynamics (MD) simulation, one of the two fundamental methods of computational chemistry, 
was used for the macromolecules-bound conformations to smaller molecules was used in this current 
research. This chapter will hence begin describing the computational chemistry theories found in both 
molecular mechanics (MM) and MD: Potential energy surface (PES); Born and Oppenheimer; the 
Schrödinger’s equation, followed by the application of MM and MD methods used in our investigations.  
3.2. Schrödinger’s equation 
The Schrödinger’s equation is the principal equation of physics, which describes quantum mechanical 
behavior190. It defines the dynamics of physical systems for isolated quantum systems191. There are two 
sorts of Schrödinger equation: One which is time-dependent thus describes how the wave function of a 
particle changes over time192 and the other one which is time-independent explain the permissible 
energies for the particle193. Hence the names time dependent Schrödinger equation and time independent 
Schrödinger equation respectively. Hamiltonian operator is defined by time dependent Schrödinger 




the kinetic energy and the potential energy194. The sum of the kinetic energy and the potential energy are 
presented in the following equation:  
      H = T + V                                                Eq. 1 
Where H represents Hamiltonian operator, kinetic energy defined by T and the potential energy by V.  H 
can alternatively be represented by the following equation: 
                                 H =  −
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)                         Eq. 2 
3.3. Born-Oppenheimer approximation 
The Born-Oppenheimer approximation is precisely a major part of an everyday quantum analysis of 
atoms and molecules195, which was first introduced in 1927 post to the Schrödinger equation 
publication196. The Born-Oppenheimer approximation is centered on the nuclei being heavier than 
electrons by numerous thousand197. The molecular system’s energy structure and the conditions of 
quantum can be merely determined in two steps198 which involves the resolution of Schrödinger’s 
equation. First step is to resolve Schrödinger’s equation by holding the nuclei in space at a fixed 
position194,199 and the second is by obtaining the PES based on resolving the Hamiltonian principle using 
the first step’s energy200. These steps are well defined using the following equations: 
Step1:       (𝒓,)= 𝑬𝒆𝒇𝒇(𝑹)𝝋𝒆𝒍𝒆𝒄(𝒓,𝑹)                Eq. 3 
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 )]              Eq. 4 
3.4. Potential Energy Surface 
A potential energy surface (PES) is a mathematical function that describes how the energy of a molecule 
is dissimilar to its geometry201. This energy is given as a function of stretches, bends and torsions by MM 
and QM gives an energy function, which can be the same in principle and works for any molecule202. Ab 
initio is a method used in determining PES and electronic structure calculation can be performed in a 
large number203, which is relevant for accurately describing the whole PES204. The Figure 3.1 below best 






Figure 3.1: Three-dimensional structure of Potential energy surface adapted from205.   
 
3.5. Molecular Mechanics 
Molecular mechanics (MM) is a model used in the calculation of the energy of the complex from which 
the energy of both the free ligand and the receptor can be obtained206. Force fields are used to calculate 
the potential energy of all systems in MM207. Small molecules as well as large biological systems or 
material assemblies with many thousands to millions of atoms can be studied using MM208. Molecular 
mechanics potential energy functions have been used to calculate binding constants209, protein folding 
kinetics210, protonation equilibria211, active site coordinates212 and to design binding sites213. The setbacks 
of MM are that it is circumscribed by parameters of equations (i.e. a different force-field for different 
types of atoms) and is not applicable for electronic properties214–216. Molecular mechanics articulates the 
total energy as a sum of Taylor series expansions for stretches for every pair of bonded atoms, and adds 
additional potential energy terms coming from bending, torsional energy, van der Waals energy, 
electrostatics and cross terms217,218:  
     E= Estr +Ebend +Etors +Evdw +Eel +Ecross.                               Eq. 5 
Molecular mechanics attempts to make the remaining constants more transferrable among molecules than 





3.5.1. Force fields 
A force field is a mathematical function in combination with parameters that foretells the energy 
associated with the conformation of a molecule217,219. The widely used bio-molecular force fields include 
Amber, CHARMM, GROMOS, and OPLS-AA220. Each force-field is in possession of diverse parameters, 
therefore, they must be attuned to give results of the forces acting within a molecule. AMBER Force Field 
(GAFF) was used in our study to set parameters for the ligands while the standard AMBER force field 
was used for the human Hsp90 homologue and HIV-RT221. A comprehensive discussion about the 
AMBER force field is included in chapter 5. 
3.6. Molecular Dynamics simulations 
Molecular dynamics simulations have become a primary tool for the exploration of biomolecules222. Bio-
molecular dynamics simulations, to date has three major areas of application which are to bring bio-
molecular structures alive, calculates thermal averages of molecular properties and explores the thermally 
accessible conformations of a molecule or a complex223. The three commonly used simulation methods 
for molecular systems include Monte Carlo, Brownian dynamics and molecular dynamics224,225. Monte 
Carlo method is a vital tool for the estimation of the average properties of systems possessing a large 
number of accessible states226. Brownian dynamics technique is used to study the large-scale dynamics of 
macromolecules and nanoparticles diluted solution227. Molecular dynamics is proficient of simulating an 
enormous diverse systems both in and out of thermodynamic equilibrium228 and codes such as 
LAMMPS229, DLPOLY230, GROMACS231, NAMD232 and ESPResSO233. The calculations for MD 
simulations are centered on MM principles, and the newton’s laws of motion is incorporated to create 
conformations234. The results are in a form of trajectories that specifies how the particle position and 
velocity varies with time235. The trajectories results from determining the force (𝐹𝑖) for each particle as a 
function of time, which is equivalent to the negative gradient of the potential energy 
𝑭𝒊 = − 
𝑈
𝑟𝑖
                                     Eq. 6 
The potential energy function is represented by U and the position of the particle by r, whereas 
acceleration (a) of a particle is calculated by dividing the force by the mass of a particle represented by 
Newton’s Laws of Motion equation below:  
                                                                                 𝒂𝒊=− 
𝐹𝑖
𝑚𝑖 
                                        Eq. 7 
 
The change in velocity is equal to the integral of acceleration over time and the change in position is 




                                                                                   𝒅𝒗 = ∫𝒂𝒅𝒕,                                                Eq. 8 
                                                                                  𝒅𝒓 = ∫𝒗𝒅𝒕,                                                 Eq. 9 
Lastly, the kinetic energy is equal to the velocities and momenta of the given particles: 




𝑁 𝒎𝒊𝒗𝒊                                                                                      Eq. 10 
Therefore, the sum of kinetic and potential energies gives the total energy of a given system and is called 
Hamiltonian (H):  
                                                                                (𝒒,𝒑)=(𝒑)+𝑼(𝒒)                                                    Eq. 11 
A set of Cartesian coordinates is defined as q, momenta of the particles as p and the potential energy 
function as U (q). The velocities, vi (t), are the first derivatives of the positions with respect to time:  
                                                               (𝒕)= (𝒕)                                                          Eq. 12 
The atomic positions at a specific time (t) are defined by (𝑡). New positions and velocities of the atoms at 
a given time (t) and the atoms will migrate to these new positions due to the initial atom coordinates of a 
particular system. Thus, the generation of new conformations and the system’s temperature is directly 
proportional to the average kinetic energy185,235. 
3.7. Approaches for estimating binding affinities 
3.7.1. Molecular docking 
Molecular docking technique docks micro-molecules into the active site of the protein and try to detect 
the precise poses of the ligand in the active site of the protein at the same time predicting the binding 
affinity between the ligand and the protein236. The equation used in the calculation of ligand-receptor 
binding energy is as follows:  
                                               𝑬𝒃𝒊𝒏𝒅𝒊𝒏𝒈=𝑬𝒕𝒂𝒓𝒈𝒆𝒕+𝑬𝒍𝒊𝒈𝒂𝒏𝒅+𝑬𝒕𝒂𝒓𝒈𝒆𝒕−𝒍𝒊𝒈𝒂𝒏𝒅                                                   Eq. 13 
It has become a vital tool for drug discovery237. Docking can be accomplished over two interconnected 
steps: first by the selection of conformations of the ligand in the protein’s active site; then ranking the 
conformations according to a scoring function238. A number of different docking programs, based on 
different algorithms, include DOCK239,  FTDOCK240, FLOG241, GOLD242, FlexX243, AutoDock244, 
SANDOCK245, which were established to perform molecular docking studies. All of these programs can 
be classified into four broader categories: stochastic Monte Carlo, fragment-based, evolutionary-based, 
and the shape complementary method246. The two types of docking include rigid body and flexible 
docking247. In this research study an advanced version of AutoDock (AutoDock Vina) was used as the 
docking method248. Different areas applies molecular docking including: virtual screening (hit 




receptor, protein-protein interaction, structure-function studies, enzymatic reaction mechanisms, protein 
engineering and binding-site identification (blind docking)249. Protein-ligand docking is the most distinct 
docking, which is used to predict the biological activity of a ligand250.  AutoDock however has some 
shortcomings including: 
Posing: The process of determining the correct conformation and orientation of a ligand’s binding mode 
into the target’s active site. 
Scoring: The pose score is a measure of the fit of a ligand into the active site. Scoring during the posing 
phase usually comprises of simple energy calculations such as electrostatic, Van der Waals and ligand 
strain. Furthermore, the re-scoring might attempt to estimate more accurately the binding free energy and 
perchance include properties like entropy and solvation. 
Implementation of hybrid methods has been reported to create improved algorithms251.  
3.7.2. Binding free energy calculations 
The binding free energy calculations allow a complete analysis of the amount of energies that are 
responsible for molecular stability or binding affinity. The Molecular Mechanics Poisson–Boltzmann 
Surface Area (MM/PBSA) method252 was used in this study to estimate binding energies. Previous studies 
also documented that Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) calculates free 
binding energy better than MM/PBSA253. In the current study, the free binding energy of HIV-RT-
ZINC54359621 complex and C-A1-Hsp90 was analyzed using the MM/GBSA method254–257 to validate 
the docking studies. A brief description about free binding energy calculation is provided in both chapter 
4 and 5. 
3.7.3. Entropy calculations 
Entropy can be defined as the vital information to measure the degree of disorder of a thermodynamic 
system258. Entropy forms a major role in all simulations hence if not accurate it causes a setback259,260. In 
drug design the binding affinity optimization of lead compounds or known drugs is normally 
accomplished by the substitution of atoms or groups of atoms in the molecule or by limiting the 
conformational freedom of the molecules as a result increasing the binding affinity, that is, induce a 
favorable change in binding free enthalpy (ΔGbind)261.  The free energy of the system is equal to the sum of 
its enthalpy (H) plus the product of the temperature (Kelvin) and the entropy (S) of the system262. Gibbs 
free energy of reaction for calculating entropy is presented by the following equation:  
        ΔG = ΔH – TΔS                                    Eq. 14 
Thus       ΔS = 
𝚫𝑮
𝚫𝑯−𝑻





Where Δ𝐺 is free binding energy, and Δ𝐻 is enthalpy Δ𝑆 is entropy and T is the temperature. 
3.8. Modeling tools used in this study 
3.8.1. Per-residue energy decomposition analysis 
Per-residue energy decomposition (PRED) defines the specific energy contributed by each amino acid 
residue in a protein towards the binding of the ligand263. The bond formation of the molecule-molecule 







(1) Kore, S. D., Kanwar, A. J., Vinay, K., and Wanchu, A. (2013) Pattern of mucocutaneous 
manifestations in human immunodeficiency virus-positive patients in North India. Indian J. Sex. Transm. 
Dis. 34, 19–24. 
(2) Moonsamy, S., Dash, R. C., and Soliman, M. E. S. (2014) Integrated computational tools for 
identification of CCR5 antagonists as potential HIV-1 entry inhibitors: Homology modeling, virtual 
screening, molecular dynamics simulations and 3D QSAR analysis. Molecules 19, 5243–5265. 
(3) UNAIDS. (2013) Report on the global AIDS epidemic . 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf. 
(4) Buot, M.-L. G., Docena, J. P., Ratemo, B. K., Bittner, M. J., Burlew, J. T., Nuritdinov, A. R., and 
Robbins, J. R. (2014) Beyond race and place: distal sociological determinants of HIV disparities. PLoS 
One 9, e91711. 
(5) Drimie, S. (2002) The Impact of HIV/AIDS on Rural Households and Land Issues in Southern and 
Eastern Africa. http://www.fao.org/3/a-ad696e.pdf. 
(6) Tomasselli, A. G., and Heinrikson, R. L. (2000) Targeting the HIV-protease in AIDS therapy: a 
current clinical perspective. Biochim. Biophys. Acta - Protein Struct. Mol. Enzymol. 1477, 189–214. 
(7) Reeves, J. D., and Piefer, A. J. (2005) Emerging drug targets for antiretroviral therapy. Drugs 65, 
1747–66. 
(8) Ptak, R. G., Fu, W., Sanders-Beer, B. E., Dickerson, J. E., Pinney, J. W., Robertson, D. L., Rozanov, 
M. N., Katz, K. S., Maglott, D. R., Pruitt, K. D., and Dieffenbach, C. W. (2008) Cataloguing the HIV type 
1 human protein interaction network. AIDS Res. Hum. Retroviruses 24, 1497–502. 
(9) Arhel, N., and Kirchhoff, F. (2010) Host proteins involved in HIV infection: new therapeutic targets. 
Biochim. Biophys. Acta 1802, 313–21. 
(10) Coffin, J. M., Hughes, S. H., and Varmus, H. E. (1997) Overview of Reverse Transcription. Spring 
Harbor Laboratory Press. 
(11) Schauer, G., Leuba, S., and Sluis-Cremer, N. (2013) Biophysical Insights into the Inhibitory 
Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors. Biomolecules 3, 889–904. 
(12) Chiu, T. K., and Davies, D. R. (2004) Structure and function of HIV-1 integrase. Curr. Top. Med. 
Chem. 4, 965–77. 
(13) Camarasa, M.-J., Velázquez, S., San-Félix, A., Pérez-Pérez, M.-J., and Gago, F. (2006) Dimerization 
inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three 
HIV enzymes? Antiviral Res. 71, 260–7. 
(14) Arts, E. J., and Hazuda, D. J. (2012) HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. 




(15) Das, K., Lewi, P. J., Hughes, S. H., and Arnold, E. (2005) Crystallography and the design of anti-
AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-
nucleoside HIV-1 reverse transcriptase inhibitors. Prog. Biophys. Mol. Biol. 88, 209–31. 
(16) De Clercq, E. (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the 
therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, 
San Diego, CA, 5–10 April 1998.1. Antiviral Res. 38, 153–179. 
(17) Abram, M. E., Ferris, A. L., Das, K., Quinoñes, O., Shao, W., Tuske, S., Alvord, W. G., Arnold, E., 
and Hughes, S. H. (2014) Mutations in HIV-1 Reverse Transcriptase Affect the Errors Made in a Single 
Cycle of Viral Replication 88, 7589–7601. 
(18) Mbisa, J. L., Nikolenko, G. N., and Pathak, V. K. (2005) Mutations in the RNase H primer grip 
domain of murine leukemia virus reverse transcriptase decrease efficiency and accuracy of plus-strand 
DNA transfer. J. Virol. 79, 419–27. 
(19) Singh, K., Marchand, B., Kirby, K. A., Michailidis, E., and Sarafianos, S. G. (2010) Structural 
Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase. Viruses 2, 606–638. 
(20) Janssen, P. A. J., Lewi, P. J., Arnold, E., Daeyaert, F., de Jonge, M., Heeres, J., Koymans, L., 
Vinkers, M., Guillemont, J., Pasquier, E., Kukla, M., Ludovici, D., Andries, K., de Béthune, M.-P., 
Pauwels, R., Das, K., Clark, A. D., Frenkel, Y. V., Hughes, S. H., Medaer, B., De Knaep, F., Bohets, H., 
De Clerck, F., Lampo, A., Williams, P., and Stoffels, P. (2005) In search of a novel anti-HIV drug: 
multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-
dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 48, 
1901–9. 
(21) Pauwels, R. (2004) New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development 
for the treatment of HIV infections. Curr. Opin. Pharmacol. 4, 437–46. 
(22) Zhan, P., Liu, X., Li, Z., Fang, Z., Li, Z., Wang, D., Pannecouque, C., and Clercq, E. De. (2009) 
Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary 
SAR studies. Bioorg. Med. Chem. 17, 5920–7. 
(23) Das, K., Bauman, J. D., Clark, A. D., Frenkel, Y. V, Lewi, P. J., Shatkin, A. J., Hughes, S. H., and 
Arnold, E. (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: 
strategic flexibility explains potency against resistance mutations. Proc. Natl. Acad. Sci. U. S. A. 105, 
1466–71. 
(24) Petropoulos, C. J., Parkin, N. T., Limoli, K. L., Lie, Y. S., Wrin, T., Huang, W., Tian, H., Smith, D., 
Winslow, G. A., Capon, D. J., and Whitcomb, J. M. (2000) A Novel Phenotypic Drug Susceptibility 
Assay for Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 44, 920–928. 
(25) Li, H., Zheng, M., Luo, X., and Zhu, W. (2008) Computational Approaches in Drug Discovery and 
Development. Wiley Encycl. Chem. Biol. 1–9. 
(26) Ilina, T., Labarge, K., Sarafianos, S. G., Ishima, R., and Parniak, M. A. (2012) Inhibitors of HIV-1 




(27) Bernardo, C. E. P., and Silva, P. J. (2014) Computational development of rubromycin-based lead 
compounds for HIV-1 reverse transcriptase inhibition. PeerJ 2, e470. 
(28) Villavicencio, R.G. and Billones, J. B. (2009) Computational Studies of Dipyridodiazepinones as 
Human Immunodeficiency Virus ( HIV) Reverse Transcriptase Inhibitors. Philipp. J. Sci. 138, 105–113. 
(29) Bhakat, S., and Vipperla, B. (2013) Designing and computational study of some novel lamivudine 
analogues as potential hiv-1 reverse transcriptase inhibitors: analysis of the binding interactions using 
qsar, molecular docking and molecular dynamics simulation study. Int. J. Pharm. Pharm. Sci. 5, 367–373. 
(30) Sapre, N. S., Bhati, T., Gupta, S., Pancholi, N., Raghuvanshi, U., Dubey, D., Rajopadhyay, V., and 
Sapre, N. (2011) Computational modeling studies on anti-HIV-1 non-nucleoside reverse transcriptase 
inhibition by dihydroalkoxybenzyloxopyrimidines analogues: an electrotopological atomistic approach. J. 
Biophys. Chem. 02, 361–372. 
(31) Ivetac, A., Swift, S. E., Boyer, P. L., Diaz, A., Naughton, J., Young, J. A. T., Hughes, S. H., and 
McCammon, J. A. (2014) Discovery of novel inhibitors of HIV-1 reverse transcriptase through virtual 
screening of experimental and theoretical ensembles. Chem. Biol. Drug Des. 83, 521–31. 
(32) Seniya, C., Yadav, A., Khan, G., and Sah, N. (2015) In-silico studies show potent inhibition of HIV-
1 Reverse Transcriptase activity by a herbal drug. IEEE/ACM Trans. Comput. Biol. Bioinforma. 5963, 1–
1. 
(33) McInnes, C. (2007) Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 11, 494–
502. 
(34) Walters, W. P., Stahl, M. T., and Murcko, M. A. (1998) Virtual screening – an overview 3, 160–178. 
(35) Cheng, T., Li, Q., Zhou, Z., Wang, Y., and Bryant, S. H. (2012) Structure-Based Virtual Screening 
for Drug Discovery: a Problem-Centric Review. AAPS J. 14, 133–141. 
(36) Lyne, P. D. (2002) Structure-based virtual screening : an overview 7, 1047–1055. 
(37) Al, V. et. (2011) Virtual screening studies on HIV-1 reverse transcriptase inhibitors to design potent 
leads. Eur. J. Med. Chem. 46, 851–9. 
(38) Pirhadi, S., and Ghasemi, J. B. (2012) Pharmacophore Identification, Molecular Docking, Virtual 
Screening, and In Silico ADME Studies of Non-Nucleoside Reverse Transcriptase Inhibitors. Mol. 
Inform. 31, 856–866. 
(39) Poongavanam, V., and Kongsted, J. (2013) Virtual screening models for prediction of HIV-1 RT 
associated RNase H inhibition. PLoS One 8, e73478. 
(40) Vozzolo, L., Loh, B., Gane, P. J., Tribak, M., Zhou, L., Anderson, I., Nyakatura, E., Jenner, R. G., 
Selwood, D., and Fassati, A. (2010) Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and 
the capsid protein. J. Biol. Chem. 285, 39314–28. 




(42) Ivetac, A., and McCammon, J. A. (2009) Elucidating the inhibition mechanism of HIV-1 non-
nucleoside reverse transcriptase inhibitors through multicopy molecular dynamics simulations. J. Mol. 
Biol. 388, 644–58. 
(43) Singh, K., Marchand, B., Kirby, K. a., Michailidis, E., and Sarafianos, S. G. (2010) Structural 
aspects of drug resistance and inhibition of HIV-1 reverse transcriptase. Viruses 2, 606–638. 
(44) Soliman, M. E. S. (2013) A Hybrid Structure/Pharmacophore-Based Virtual Screening Approach to 
Design Potential Leads: A Computer-Aided Design of South African HIV-1 Subtype C Protease 
Inhibitors. Drug Dev. Res. 74, 283–295. 
(45) Vyas, V., Jain, A., Jain, A. and Gupta, A. (2008) Virtual Screening: A Fast Tool for Drug Design. 
Sci Pharm. 76, 333–360. 
(46) Vyas, V., Jain, A., Jain, A., and Gupta, A. (2008) Virtual screening: A fast tool for drug design. Sci. 
Pharm. 76, 333–360. 
(47) Lavecchia, A., and Di Giovanni, C. (2013) Virtual screening strategies in drug discovery: a critical 
review. Curr. Med. Chem. 20, 2839–60. 
(48) Young, D. C. (2009) Computational Drug Design: A Guide for Computational and Medicinal 
Chemists, in Computational Drug Design: A Guide for Computational and Medicinal Chemists, pp 1–
307. 
(49) Yang, S.-Y. (2010) Pharmacophore modeling and applications in drug discovery: challenges and 
recent advances. Drug Discov. Today 15, 444–450. 
(50) Mallipeddi, P. L., Kumar, G., White, S. W., and Webb, T. R. (2014) Recent Advances in Computer-
Aided Drug Design as Applied to Anti-Influenza Drug Discovery. Curr. Top. Med. Chem. 1875–1889. 
(51) Drwal, M. N., Griffith, R., and Willett, P. (2013) Enhancing the effectiveness of ligand-based virtual 
screening using data fusion. Drug Discov. Today Technol. 25, e395–e401. 
(52) Willett, P. (2006) Enhancing the effectiveness of ligand-based virtual screening using data fusion. 
QSAR Comb. Sci. 25, 1143–1152. 
(53) Drwal, M. N., and Griffith, R. (2013) Combination of ligand- and structure-based methods in virtual 
screening. Drug Discov. Today Technol. 10, e395–e401. 
(54) Khanna, M., Wang, F., Jo, I., Knabe, W. E., Wilson, S. M., Li, L., Bum-erdene, K., Li, J., Sledge, G. 
W., Khanna, R., and Meroueh, S. O. (2011) Targeting Multiple Conformations Leads to Small Molecule 
Inhibitors. ACS Chem. Biol. 6, 1232–1243. 
(55) Amaro, R. E., Baron, R., and McCammon, J. A. (2008) An improved relaxed complex scheme for 
receptor flexibility in computer-aided drug design. J. Comput. Aided. Mol. Des. 22, 693–705. 
(56) Okimoto, N., Futatsugi, N., Fuji, H., Suenaga, A., Morimoto, G., Yanai, R., Ohno, Y., Narumi, T., 
and Taiji, M. (2009) High-performance drug discovery: Computational screening by combining docking 




(57) Wang, L., Gu, Q., Zheng, X., Ye, J., Liu, Z., Li, J., Hu, X., Hagler, A., and Xu, J. (2013) Discovery 
of new selective human aldose reductase inhibitors through virtual screening multiple binding pocket 
conformations. J. Chem. Inf. Model. 53, 2409–2422. 
(58) Rastelli, G. (2013) Emerging topics in structure-based virtual screening. Pharm. Res. 30, 1458–1463. 
(59) Skelton, A. a., Maharaj, Y. R., and Soliman, M. E. S. (2014) Target-bound generated pharmacophore 
model to improve the pharmacophore-based virtual screening: Identification of G-protein human CCR2 
receptors inhibitors as anti-inflammatory drugs. Cell. Mol. Bioeng. 7, 45–57. 
(60) Islam, A., and Pillay, T. S. (2012) Exploration of the structural requirements of HIV-protease 
inhibitors using pharmacophore , virtual screening and molecular docking approaches for lead 
identification, pp 1–29. 
(61) Peterson, L. B. (2012) Investigation of the Hsp90 C-terminal Binding Site, Novel Inhibitors and 
Isoform-Dependent Client Proteins. University of Kansas. 
http://kuscholarworks.ku.edu/handle/1808/10218. 
(62) Sharp, P. M., and Hahn, B. H. (2011) Origins of HIV and the AIDS pandemic. Cold Spring Harb. 
Perspect. Med. 1, a006841. 
(63) Norris, N. (2011) HIV/AIDS-Past,Present and Future. Libr. Parliam. 
(64) Levy, J. A. (1993) Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57, 
183–289. 
(65) Sharp, P.M. and Hahn, B. H. (2010) The evolution of HIV-1 and the origin of AIDS. Philos. Trans. 
R. Soc. B. 365, 2487–2494. 
(66) Fischer, N and Madden, D. (2011) The origins and evolution of HIV. http://www.dnadarwin.org/. 
(67) Campbell-Yesufu, O. T., and Gandhi, R. T. (2011) Update on human immunodeficiency virus 
(HIV)-2 infection. Clin. Infect. Dis. 52, 780–7. 
(68) Simon, V., Ho, D. D., and Abdool Karim, Q. (2006) HIV/AIDS epidemiology, pathogenesis, 
prevention, and treatment. Lancet 368, 489–504. 
(69) Sweat, M. D., and Denison, J. A. (1995) Reducing HIV incidence in developing countries with 
structural and environmental interventions. AIDS 9 Suppl A, S251–7. 
(70) Dixon, S., McDonald, S., and Roberts, J. (2002) The impact of HIV and AIDS on Africa’s economic 
development. BMJ 324, 232–4. 
(71) Stover, J. and Bollinger, L. (1999) The Economic Impact of AIDS. 
http://pdf.usaid.gov/pdf_docs/Pnacm899.pdf. 
(72) AIDS.gov. (2014). The global HIV/AIDS epidemic.Https://www.aids.gov/hiv-aids-basics/hiv-aids-




(73) UNAIDS. (2013). AIDS by the numbers. 
http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf. 
(74) Launch of the 2012 South African National HIV Prevalence, Incidence and Behaviour Survey 
Report: http://www.hsrc.ac.za/en/media-briefs/hiv-aids-stis-and-tb/sabssm4-
launch#sthash.4ATzvU5m.dpuf. 
(75) Engelman, A. and Cherepanov, P. (2012) The structural biology of HIV-1: mechanistic and 
therapeutic insights. Nat. Rev. | Microbiol. 10, 279. 
(76) WebMD:HIV (Human Immunodeficiency Virus) Infection. http://www.webmd.com/hiv-
aids/tc/human-immunodeficiency-virus-hiv-infection-topic-overview. 
(77) Watts, J. M., Dang, K. K., Gorelick, R. J., Leonard, C. W., Bess, J. W., Swanstrom, R., Burch, C. L., 
and Weeks, K. M. (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 
460, 711–6. 
(78) Malim, M. H., and Emerman, M. (2008) HIV-1 accessory proteins--ensuring viral survival in a 
hostile environment. Cell Host Microbe 3, 388–98. 
(79) Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., and 
Elledge, S. J. (2008) Identification of host proteins required for HIV infection through a functional 
genomic screen. Science 319, 921–6. 
(80) Fenner, J. (2013) Virulent A3/02 HIV Strain Leads to AIDS Within Five Years. Liberty voice. 
(81) AIDSMEDS. (2008) The HIV Life Cycle : Introduction. 
Http://www.aidsmeds.com/articles/hiv_life_cycle_5014.shtml. 
(82) AIDSinfo. (2005) The HIV Life Cycle. 
http://medicine.nevada.edu/Documents/unsom/statewide/aidsetc/HIVLifeCycle_FS_en.pdf. 
(83) Barré-Sinoussi, F., Ross, A. L., and Delfraissy, J.-F. (2013) Past, present and future: 30 years of HIV 
research. Nat. Rev. Microbiol. 11, 877–83. 
(84) Wilen, C. B., Tilton, J. C., and Doms, R. W. (2012) HIV: Cell binding and entry. Cold Spring Harb. 
Perspect. Med. 2, 1–14. 
(85) Hunter, E. (2002) Viral Binding and Fusion—The Next Targets in Antiretroviral Therapy. Int. ADIS 
Soc. USA 10. 
(86) Mary Ann Checkley, B. G. L. and E. O. F. (2011) HIV-1 Envelope Glycoprotein Biosynthesis, 
Trafficking, and Incorporation. J. Mol. Biol. 410, 582–608. 
(87) Briz, V., Poveda, E., and Soriano, V. (2006) HIV entry inhibitors: mechanisms of action and 
resistance pathways. J. Antimicrob. Chemother. 57, 619–27. 
(88) Vetrivel, U., Sankar, P., kumar Nagarajan, N., and Subramanian, G. (2009) Peptidomimetics Based 




(89) Tsou, L. K., Chen, C.-H., Dutschman, G. E., Cheng, Y.-C., and Hamilton, A. D. (2012) Blocking 
HIV-1 entry by a gp120 surface binding inhibitor. Bioorg. Med. Chem. Lett. 22, 3358–61. 
(90) Patil, A. D., Kumar, N. V., Kokke, W. C., Bean, M. F., Freyer, A. J., Brosse, C. De, Mai, S., Truneh, 
A., and Carte, B. (1995) Novel Alkaloids from the Sponge Batzella sp.: Inhibitors of HIV gp120-Human 
CD4 Binding. J. Org. Chem. 60, 1182–1188. 
(91) Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, 
R., Yamanaka, G., Robinson, B., Li, C.-B., Fridell, R., Deminie, C., Demers, G., Yang, Z., Zadjura, L., 
Meanwell, N., and Colonno, R. (2003) A small molecule HIV-1 inhibitor that targets the HIV-1 envelope 
and inhibits CD4 receptor binding. Proc. Natl. Acad. Sci. U. S. A. 100, 11013–8. 
(92) Kadow, J., Wang, H.-G. H., and Lin, P.-F. (2006) Small-molecule HIV-1 gp120 inhibitors to prevent 
HIV-1 entry: an emerging opportunity for drug development. Curr. Opin. Investig. Drugs 7, 721–6. 
(93) Lieberman-Blum, S. S., Fung, H. B., and Bandres, J. C. (2008) Maraviroc: a CCR5-receptor 
antagonist for the treatment of HIV-1 infection. Clin. Ther. 30, 1228–50. 
(94) Rao, P. K. S. (2009) CCR5 inhibitors: Emerging promising HIV therapeutic strategy. Indian J. Sex. 
Transm. Dis. 30, 1–9. 
(95) Steen, A., and Rosenkilde, M. M. (2012) Novel Developments in Stem Cell Mobilization. Focus 
(Madison). 23–36. 
(96) Zhang, Y., Patel, S., Abdelouahab, H., Wittner, M., Willekens, C., Shen, S., Betems, A., Joulin, V., 
Opolon, P., Bawa, O., Pasquier, F., Ito, M., Fujii, N., Gonin, P., Solary, E., Vainchenker, W., Coppo, P., 
De Botton, S., and Louache, F. (2012) CXCR4 inhibitors selectively eliminate CXCR4-expressing human 
acute myeloid leukemia cells in NOG mouse model. Cell Death Dis. 3, e396. 
(97) Hatse, S., Princen, K., Bridger, G., De Clercq, E., and Schols, D. (2002) Chemokine receptor 
inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 527, 255–262. 
(98) Debnath, B., Xu, S., Grande, F., Garofalo, A., and Neamati, N. (2013) Small Molecule Inhibitors of 
CXCR4. Theranostics 3, 47–75. 
(99) Arakaki, R., Tamamura, H., Premanathan, M., Kanbara, K., Ramanan, S., Mochizuki, K., Baba, M., 
Fujii, N., and Nakashima, H. (1999) T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug 
Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure. J. Virol. 73, 1719–1723. 
(100) Frey, G., Rits-Volloch, S., Zhang, X.-Q., Schooley, R. T., Chen, B., and Harrison, S. C. (2006) 
Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc. Natl. 
Acad. Sci. U. S. A. 103, 13938–43. 
(101) Kahle, K. M., Steger, H. K., and Root, M. J. (2009) Asymmetric deactivation of HIV-1 gp41 
following fusion inhibitor binding. PLoS Pathog. 5, e1000674. 
(102) Liu, S., Wu, S., and Jiang, S. (2007) HIV entry inhibitors targeting gp41: from polypeptides to 




(103) Qiu, S., Yi, H., Hu, J., Cao, Z., Wu, Y., and Li, W. (2012) The binding mode of fusion inhibitor 
T20 onto HIV-1 gp41 and relevant T20-resistant mechanisms explored by computational study. Curr. 
HIV Res. 10, 182–94. 
(104) Root, M. J., and Steger, H. K. (2004) HIV-1 gp41 as a target for viral entry inhibition. Curr. Pharm. 
Des. 10, 1805–25. 
(105) Zhou, G., and Chu, S. (2013) Discovery of small molecule fusion inhibitors targeting HIV-1 gp41. 
Curr. Pharm. Des. 19, 1818–26. 
(106) Hu, W.-S., and Hughes, S. H. (2012) HIV-1 reverse transcription. Cold Spring Harb. Perspect. 
Med. 2, a006882–. 
(107) Telesnitsky, A., and Goff, S. (1997) Reverse Transcriptase and the Generation of Retroviral DNA. 
Cold Spring Harbor Laboratory Press. 
(108) Craigie, R., and Bushman, F. D. (2012) HIV DNA integration. Cold Spring Harb. Perspect. Med. 2, 
a006890. 
(109) Engelman, A., Mizuuchi, K., and Craigie, R. (1991) HIV-1 DNA integration: Mechanism of viral 
DNA cleavage and DNA strand transfer. Cell 67, 1211–1221. 
(110) Bushman, F. D., and Craigie, R. (1991) Activities of human immunodeficiency virus (HIV) 
integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. 88, 
1339–1343. 
(111) Karn, J., and Stoltzfus, C. M. (2012) Transcriptional and posttranscriptional regulation of HIV-1 
gene expression. Cold Spring Harb. Perspect. Med. 2, a006916. 
(112) Buxton, P., Tachedjian, G., and Mak, J. (2005) Analysis of the contribution of reverse transcriptase 
and integrase proteins to retroviral RNA dimer conformation. J. Virol. 79, 6338–48. 
(113) Frankel, A. D. (1992) Activation of HIV transcription by Tat 2, 293–298. 
(114) Boireau, S., Maiuri, P., Basyuk, E., de la Mata, M., Knezevich, A., Pradet-Balade, B., Bäcker, V., 
Kornblihtt, A., Marcello, A., and Bertrand, E. (2007) The transcriptional cycle of HIV-1 in real-time and 
live cells. J. Cell Biol. 179, 291–304. 
(115) AVERT. (2015) HIV Structure and Life Cycle. http://www.avert.org/hiv-structure-and-life-
cycle.htm. 
(116) AIDSMEDS. (2008) The HIV Life Cycle : Step 6: Viral Assembly and Maturation. 
http://www.aidsmeds.com/articles/hiv_life_cycle_4711.shtml. 
(117) Palmisano, L., and Vella, S. (2011) A brief history of antiretroviral therapy of HIV infection: 
success and challenges. Ann. Ist. Super. Sanita 47, 44–8. 





(119) Atripla. (2015) Important Goals of HIV Treatment. http://www.atripla.com/goals-of-HIV-treatment. 
(120) Gu, W.-G., Zhang, X., and Yuan, J.-F. (2014) Anti-HIV drug development through computational 
methods. AAPS J. 16, 674–80. 
(121) De Clercq, E. (2009) Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an 
historical perspective. Adv. Virus Res. 73, 1–53. 
(122) G Meintjes, J Black, F Conradie, V Cox, S Dlamini, J Fabian, G Maartens, T Manzini, M Mathe, C 
Menezes, M Moorhouse, Y. M., and J Nash, C Orrell, Y Pakade, F Venter, D. W. (2014) Adult 
antiretroviral therapy guidelines 2014. South. African HIV Clin. Soc. 15, 121–143. 
(123) De Béthune, M.-P. (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their 
discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-
2009). Antiviral Res. 85, 75–90. 
(124) Eggink, D., Berkhout, B., and Sanders, R. W. (2010) Inhibition of HIV-1 by fusion inhibitors. Curr. 
Pharm. Des. 16, 3716–28. 
(125) Pang, Wei Siu Tam, Cheung Yong, And Zheng, T. (2009) Inhibitors, Current peptide HIV type-1 
fusion. Antivir. Chem. Chemother. 2040–2066. 
(126) Dirk Eggink, B. B. and R. W. S. Inhibition of HIV-1 by Fusion Inhibitors. Bentham Sci. Publ. 16, 
3716 – 3728. 
(127) Qian, K., Morris-Natschke, S. L., and Lee, K.-H. (2009) HIV entry inhibitors and their potential in 
HIV therapy. Med. Res. Rev. 29, 369–93. 
(128) Bell, F. W., Cantrell, A. S., Hoegberg, M., Jaskunas, S. R., Johansson, N. G., Jordan, C. L., 
Kinnick, M. D., Lind, P., and Morin, J. M. (1995) Phenethylthiazolethiourea (PETT) Compounds, a New 
Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Synthesis and Basic Structure-Activity Relationship 
Studies of PETT Analogs. J. Med. Chem. 38, 4929–4936. 
(129) Maga, G., Radi, M., Gerard, M.-A., Botta, M., and Ennifar, E. (2010) HIV-1 RT Inhibitors with a 
Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate. Viruses 2, 880–99. 
(130) Chimirri, A., Monforte, P., Rao, A., Zappalà, M., Monforte, A., Sarro, G. De, Pannecouque, C., 
Witvrouw, M., and Clercq, J. B. and E. De. (2001) Synthesis, biological activity, pharmacokinetic 
properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: non-
nucleoside HIV-1 reverse transcriptase inhibitors. Antivir. Chem. Chemother. 12, 169–174. 
(131) Mehellou, Y. and De Clercq, E. (2009) Twenty-Six Years of Anti-HIV Drug Discovery: Where Do 
We Stand and Where Do We Go? J. Med. Chem. Perspect. 53, 521–538. 
(132) Jingshan Ren, John Milton, K. L. W., Steven A. Short, David I. Stuart, K., and Stammers, and D. K. 
(2000) Structural Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-




(133) De Béthune, M.-P. (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their 
discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-
2009). Antiviral Res. 85, 75–90. 
(134) Minuto, J. J., and Haubrich, R. (2008) Etravirine: a second-generation NNRTI for treatment-
experienced adults with resistant HIV-1 infection. Futur. HIV Ther. 2, 525–537. 
(135) AIDSmap. (2012) HIV & AIDS Information : A to Z of antiretroviral drugs - Rilpivirine (Edurant). 
http://www.aidsmap.com/resources/treatmentsdirectory/drugs/Rilpivirine-iEduranti/page/1731269/. 
(136) Temesgen, Z., and Siraj, D. S. (2008) Raltegravir: first in class HIV integrase inhibitor. Ther. Clin. 
Risk Manag. 4, 493–500. 
(137) Hicks, C., and Gulick, R. M. (2009) Raltegravir: the first HIV type 1 integrase inhibitor. Clin. 
Infect. Dis. 48, 931–9. 
(138) Lampiris, H. W. (2012) Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev. 
Anti. Infect. Ther. 10, 13–20. 
(139) Fantauzzi, A., Turriziani, O., and Mezzaroma, I. (2013) Potential benefit of dolutegravir once daily: 
efficacy and safety. HIV. AIDS. (Auckl). 5, 29–40. 
(140) Brik, A., and Wong, C.-H. (2003) HIV-1 protease: mechanism and drug discovery. Org. Biomol. 
Chem. 1, 5–14. 
(141) Fernández-Montero, J. V., Barreiro, P., and Soriano, V. (2009) HIV protease inhibitors: recent 
clinical trials and recommendations on use. Expert Opin. Pharmacother. 
(142) Farady, Christopher J. Craik, and C. S. (2010) Mechanisms of Macromolecular Protease Inhibitors. 
ChemBioChem 11, 2341 – 2346. 
(143) De Clercq, E. (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery 
of HIV. Int. J. Antimicrob. Agents 33, 307–20. 
(144) (CDC)., C. for D. C. and P. (1996) Clinical update: impact of HIV protease inhibitors on the 
treatment of HIV-infected tuberculosis patients with rifampin. MMWR. Morb. Mortal. Wkly. Rep. 45, 
921–5. 
(145) Wkipedia. (2015) Discovery and development of HIV-protease inhibitors. 
https://en.wikipedia.org/wiki/Discovery_and_development_of_HIV-protease_inhibitors. 
(146) Bec, G., Meyer, B., Gerard, M.-A., Steger, J., Fauster, K., Wolff, P., Burnouf, D., Micura, R., 
Dumas, P., and Ennifar, E. (2013) Thermodynamics of HIV-1 reverse transcriptase in action elucidates 
the mechanism of action of non-nucleoside inhibitors. J. Am. Chem. Soc. 135, 9743–52. 
(147) Restle, T., Pawlita, M., Sczakiel, G., Muller, B., and Goody, R. S. (1992) Structure-function 





(148) Abbondanzieri, E. A., Bokinsky, G., Rausch, J. W., Zhang, J. X., Le Grice, S. F. J., and Zhuang, X. 
(2008) Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 453, 184–9. 
(149) Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, S. H., and 
Arnold, E. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of 
polymerization and inhibition. J. Mol. Biol. 385, 693–713. 
(150) Chong, P., Sebahar, P., Youngman, M., Garrido, D., Zhang, H., Stewart, E. L., Nolte, R. T., Wang, 
L., Ferris, R. G., Edelstein, M., Weaver, K., Mathis, A., and Peat, A. (2012) Rational Design of Potent 
Non-Nucleoside Inhibitors of HIV -1 Reverse Transcriptase. 
(151) Goodsell, D. (2002) HIV Reverse 
Transcriptase.http://www.rcsb.org/pdb/101/motm.do?momID=33. 
(152) Bahar, I., Erman, B., Jernigan, R. L., Atilgan, A. R., and Covell, D. G. (1999) Collective motions in 
HIV-1 reverse transcriptase: examination of flexibility and enzyme function. J. Mol. Biol. 285, 1023–37. 
(153) Esposito et al. (2012) HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, 
Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions. Mol. Biol. Int. 
2012, 586401. 
(154) Hu, W.-S., and Hughes, S. H. (2012) HIV-1 reverse transcription. Cold Spring Harb. Perspect. 
Med. 2. 
(155) LeGrice, S. F. J., and Gotte, M. (2013) Human Immunodeficiency Virus Reverse Transcriptase. 
Springer Science & Business Media. 
(156) Jeeninga, R. E., Huthoff, H. T., Berkhout, B., and Gultyaev, A. P. (1998) The mechanism of 
actinomycin D-mediated inhibition of HIV-1 reverse transcription. Nucleic Acids Res. 26, 5472–5479. 
(157) McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., and Frydman, and J. 
(2007) Diverse Cellular Functions of the Hsp90 Molecular Chaperone Uncovered Using Systems 
Approaches. Cell 131, 121–135. 
(158) Johnson, J. L. (2012) Evolution and function of diverse Hsp90 homologs and cochaperone proteins. 
Biochim. Biophys. Acta - Mol. Cell Res. 1823, 607–613. 
(159) Li, J., and Buchner, J. (2013) Structure, function and regulation of the hsp90 machinery. Biomed. J. 
36, 106–17. 
(160) Neckers, L., Kern, A., and Tsutsumi, and S. (2007) Hsp90 Inhibitors Disrupt Mitochondrial 
Homeostasis in Cancer Cells. Chem. Biol. 
(161) Picard, D. (2002) Heat-shock protein 90, a chaperone for folding and regulation. Cell. Mol. Life Sci. 
59, 1640–1648. 
(162) Ciocca, D. R., and Calderwood, S. K. (2005) Heat shock proteins in cancer: diagnostic, prognostic, 




(163) Csermely, P., Schnaider, T., Soti, C., Prohászka, Z., and Nardai, G. (1998) The 90-kDa molecular 
chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol. 
Ther. 79, 129–68. 
(164) Zuehlke, A., and Johnson, J. L. (2010) Hsp90 and co-chaperones twist the functions of diverse 
client proteins. Biopolymers 93, 211–7. 
(165) Gao, J., Xiao, S., Liu, X., Wang, L., Zhang, X., Ji, Q., Wang, Y., Mo, D., and Chen, Y. (2014) 
Inhibition of HSP90 attenuates porcine reproductive and respiratory syndrome virus production in vitro. 
Virol. J. 11. 
(166) Didenko, T., Duarte, A. M. S., Karagöz, G. E., and Rüdiger, S. G. D. (2012) Hsp90 structure and 
function studied by NMR spectroscopy. Biochim. Biophys. Acta 1823, 636–47. 
(167) Ali, M. M. U., Roe, S. M., Vaughan, C. K., Meyer, P., Panaretou, B., Piper, P. W., Prodromou, C., 
and Pearl, L. H. (2006) Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex. 
Nature 440, 1013–1017. 
(168) Jahn, M., Rehn, A., Pelz, B., Hellenkamp, B., Richter, K., Rief, M., Buchner, J., and Hugel, T. 
(2014) The charged linker of the molecular chaperone Hsp90 modulates domain contacts and biological 
function. Proc. Natl. Acad. Sci. U. S. A. 111, 17881–6. 
(169) Krishna, P., and Gloor, G. (2001) The Hsp90 family of proteins in Arabidopsis thaliana. Cell Stress 
Chaperones 6, 238–46. 
(170) Nemoto, T., Sato, N., Iwanari, H., Yamashita, H., and Takagi, T. (1997) Domain structures and 
immunogenic regions of the 90-kDa heat-shock protein (HSP90). Probing with a library of anti-HSP90 
monoclonal antibodies and limited proteolysis. J. Biol. Chem. 272, 26179–87. 
(171) Prodromou, C., and Pearl, L. H. (2003) Structure and functional relationships of Hsp90. Curr. 
Cancer Drug Targets 3, 301–23. 
(172) Donnelly, A., and Blagg, B. S. J. (2008) Novobiocin and additional inhibitors of the Hsp90 C-
terminal nucleotide-binding pocket. Curr. Med. Chem. 15, 2702–17. 
(173) Den, R. B., and Lu, B. (2012) Heat shock protein 90 inhibition: rationale and clinical potential. 
Ther. Adv. Med. Oncol. 4, 211–8. 
(174) Rowlands, M., McAndrew, C., Prodromou, C., Pearl, L., Kalusa, A., Jones, K., Workman, P., and 
Aherne, W. (2010) Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using 
the TranscreenerTM ADP assay kit. J. Biomol. Screen. 15, 279–86. 
(175) Jhaveri, K., Taldone, T., Modi, S., and Chiosis, G. (2012) Advances in the clinical development of 
heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 1823, 742–55. 
(176) Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. (1997) 
Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an 




(177) Taldone, T., Gozman, A., Maharaj, R., and Chiosis, G. (2008) Targeting Hsp90: small-molecule 
inhibitors and their clinical development. Curr. Opin. Pharmacol. 8, 370–4. 
(178) Janin, Y. L. (2010) ATPase inhibitors of heat-shock protein 90, second season. Drug Discov. Today 
15, 342–353. 
(179) Sharma, S. V, Agatsuma, T., and Nakano, H. (1998) Targeting of the protein chaperone, HSP90, by 
the transformation suppressing agent, radicicol. Oncogene 16, 2639–45. 
(180) Yu, X. M., Shen, G., Neckers, L., Blake, H., Holzbeierlein, J., Cronk, B., and Blagg, B. S. J. (2005) 
Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc. 127, 12778–9. 
(181) Samuels, D. S., and Garon, C. F. (1993) Coumermycin A1 inhibits growth and induces relaxation of 
supercoiled plasmids in Borrelia burgdorferi, the Lyme disease agent. Antimicrob. Agents Chemother. 37, 
46–50. 
(182) Zhao-Xin Wang, S.-M. L. L. H. (2000, November 1) Identification of the Coumermycin A1 
Biosynthetic Gene Cluster of Streptomyces rishiriensis DSM 40489. Antimicrob. Agents Chemother. 
American Society for Microbiology (ASM). 
(183) Gormley, N. A., Orphanides, G., Meyer, A., Cullis, P. M., and Maxwell, A. (1996) The interaction 
of coumarin antibiotics with fragments of DNA gyrase B protein. Biochemistry 35, 5083–92. 
(184) Burlison, J. A., and Blagg, B. S. J. (2006) Synthesis and Evaluation of Coumermycin A1 Analogues 
that Inhibit the Hsp90 Protein Folding Machinery. Org. Lett. 8, 4855–4858. 
(185) Jensen, F. (2007) Introduction to Computational Chemistry. John Wiley son. 
(186) Gilbert, A. (2011) Introduction to Computational Chemistry: Theory. 
http://rsc.anu.edu.au/~agilbert/gilbertspace/uploads/Chem3023.pdf. 
(187) Song, C.M. Lim, S.J., And Tong, J. C. (2009) Recent advances in computer-aided drug design. - 
PubMed - NCBI. Brief. Bioinform. 10, 579–91. 
(188) Achenie, L.E.K., Gani, R. and Venkatasubramanian, V. (2002) Computer Aided Molecular Design: 
Theory and Practice. Elsevier. 
(189) Talele, T. T., Khedkar, S. a, and Rigby, A. C. (2010) Successful applications of computer aided 
drug discovery: moving drugs from concept to the clinic. Curr. Top. Med. Chem. 10, 127–141. 
(190) Weisstein, E. W. (2007) Schrödinger Equation -- from Eric Weisstein’s World of Physics. Wolfram 
Research, Inc. 
(191) Modi, K. (2012) Operational approach to open dynamics and quantifying initial correlations. Sci. 
Rep. 2, 581. 
(192) Penz, M., and Ruggenthaler, M. (2015) Functional differentiability in time-dependent quantum 




(193) Maji, K., and Kouri, D. J. (2011) Quantum mechanical generalized phase-shift approach to atom-
surface scattering: a Feshbach projection approach to dealing with closed channel effects. J. Chem. Phys. 
134, 124103. 
(194) Melchor, M. G. (2013) A Theoretical Study of Pd-Catalyzed C-C Cross-Coupling Reactions. 
Springer Science & Business Media. 
(195) Giordano, D. (2007) Impact of the Born-Oppenheimer Approximation on Aerothermodynamics. J. 
Thermophys. Heat Transf. 21, 647–657. 
(196) Born, M., and Oppenheimer, R. (1927) Zur Quantentheorie der Molekeln. Ann. Phys. 389, 457–
484. 
(197) Tuckerman, M. (2011) The Born-Oppenheimer Approximation. 
http://www.nyu.edu/classes/tuckerman/quant.mech/lectures/lecture_10/node1.html. 
(198) He, G. S. (2014) Nonlinear Optics and Photonics. Oxford University Press. 
(199) Bunker, P. R., and Jensen, P. (2006) Molecular Symmetry and Spectroscopy. NRC Research Press. 
(200) Hotokka, M., Brändas, E.J., Jean Maruani, J. and Delgado-Barrio, G. (2013) Advances in Quantum 
Methods and Applications in Chemistry, Physics, and Biology. Springer Science & Business Media. 
(201) Lewars, E. G. (2008) Modeling Marvels: Computational Anticipation of Novel Molecules. Springer 
Science & Business Media. 
(202) Sherrill, C. D. (2009) Potential Energy Surfaces. 
http://vergil.chemistry.gatech.edu/courses/chem6485/pdf/pes-lecture.pdf. 
(203) Jaquet, R. (2002) Introduction to potential energy surfaces and graphical interpretation. 
http://www.tc.chemie.uni-siegen.de/jaquet/Copy-of-introPEStexpowerlight.pdf. 
(204) Deá, P., Frauenheim, T. and Pederson, M. R. (2000) Computer Simulation of Materials at Atomic 
Level, Volume 1. John Wiley & Sons. 
(205) Rusbult, C. (2005) Quantum Physics & New Age Religion. 
http://www.chem.wayne.edu/~hbs/chm6440/PES.html. 
(206) Marshal, G. R. (1987) Computer-aided drug design. Ann. Rev. Pharmacol.toxicol. 27, 193–213. 
(207) Thakur, V. K. (2014) Lignocellulosic Polymer Composites: Processing, Characterization, and 
Properties. Wiley. 
(208) Rai, B. (2012) Molecular Modeling for the Design of Novel Performance Chemicals and Materials. 
CRC Press. 
(209) Kuhn, B., and Kollman, P. A. (2000) Binding of a diverse set of ligands to avidin and streptavidin: 
an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics 




(210) Snow, C. D., Nguyen, H., Pande, V. S., and Gruebele, M. (2002) Absolute comparison of simulated 
and experimental protein-folding dynamics. Nature 420, 102–6. 
(211) Barth, P., Alber, T., and Harbury, P. B. (2007) Accurate, conformation-dependent predictions of 
solvent effects on protein ionization constants. Proc. Natl. Acad. Sci. U. S. A. 104, 4898–903. 
(212) Chakrabarti, R., Klibanov, A. M., and Friesner, R. A. (2005) Computational prediction of native 
protein ligand-binding and enzyme active site sequences. Proc. Natl. Acad. Sci. U. S. A. 102, 10153–8. 
(213) Boas, F. E., and Harbury, P. B. (2008) Design of Protein–Ligand Binding Based on the Molecular-
Mechanics Energy Model. J. Mol. Biol. 380, 415–424. 
(214) Moult, J. (1997) Comparison of database potentials and molecular mechanics force fields. Curr. 
Opin. Struct. Biol. 7, 194–9. 
(215) Senn, H. M., and Thiel, W. (2009) QM/MM methods for biomolecular systems. Angew. Chem. Int. 
Ed. Engl. 48, 1198–229. 
(216) Foundation, T. S. E. (1999) Overview of Computational Chemistry. 
https://www.shodor.org/chemviz/overview/ccbasics.html. 
(217) Guvench, O., and MacKerell, A. D. (2008) Comparison of protein force fields for molecular 
dynamics simulations. Methods Mol. Biol. 443, 63–88. 
(218) Adcock, S. A., and McCammon, J. A. (2006) Molecular dynamics: survey of methods for 
simulating the activity of proteins. Chem. Rev. 106, 1589–615. 
(219) A., K., Rappe, C., J., Casewit, K., S., Colwell, W., A., Goddard, And, W., M., and Skid. (1994) 
UFF, a Full Periodic Table Force Field for Molecular Mechanics and Molecular Dynamics Simulations. 
J.Am.Chem.Soc 114, 10024–10035. 
(220) Hu, Z., and Jiang, J. (2009) Assessment of biomolecular force fields for molecular dynamics 
simulations in a protein crystal. J. Comput. Chem. 31. 
(221) McCammon, J. A., Gelin, B. R., and Karplus, M. (1977) Dynamics of folded proteins. Nature 267, 
585–90. 
(222) Guliaev, A. B., Cheng, S., and Hang, B. (2012) Protein dynamics via computational microscope. 
World J. Methodol. 2, 42–9. 
(223) Hansson, T., Oostenbrink, C., and van Gunsteren, W. (2002) Molecular dynamics simulations. 
Curr. Opin. Struct. Biol. 12, 190–196. 
(224) Abbas, H. and, and Balkose, D. (2014) Applied Methodologies in Polymer Research and 
Technology. CRC Press. 
(225) Hamrang, A. (2014) Materials Science and Engineering. Volume I: Physical Process, Methods, and 




(226) Frenkel, D. (2004) Speed-up of Monte Carlo simulations by sampling of rejected states. Proc. Natl. 
Acad. Sci. U. S. A. 101, 17571–5. 
(227) Ricardo Rodríguez Schmidt, José G. Hernández Cifre, and J. G. de la T. (2011) Comparison of 
Brownian dynamics algorithms with hydrodynamic interaction. J. Chem. Phys. 135. 
(228) Anderson, J. A., Lorenz, C. D., and Travesset, A. (2008) General purpose molecular dynamics 
simulations fully implemented on graphics processing units. J. Comput. Phys. 227, 5342–5359. 
(229) Plimpton, S. (1995) Fast Parallel Algorithms for Short-Range Molecular Dynamics. J. Comput. 
Phys. 117, 1–19. 
(230) Todorov, I.T. and Smith, W. (2015) The DL-POLY-4 user manual. 
http://www.ccp5.ac.uk/DL_POLY/MANUALS/USRMAN4.pd. 
(231) Berendsen, H. J. C., van der Spoel, D., and van Drunen, R. (1995) GROMACS: A message-passing 
parallel molecular dynamics implementation. Comput. Phys. Commun. 91, 43–56. 
(232) Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. 
D., Kalé, L., and Schulten, K. (2005) Scalable molecular dynamics with NAMD. J. Comput. Chem. 26, 
1781–802. 
(233) Limbach, H. J., Arnold, A., Mann, B. A., and Holm, C. (2006) ESPResSo—an extensible 
simulation package for research on soft matter systems. Comput. Phys. Commun. 174, 704–727. 
(234) Jensen, F. (2007) Introduction to Computational Chemistry 2nd Editio. Wiley. 
(235) Donald, B.B. and Kenny, B. L. (2001) Reviews in Computational Chemistry Volume 17. Rev. 
Comput. Chem. Vol. 17. 
(236) Huang, Z. (2007) Drug Discovery Research: New Frontiers in the Post-Genomic Era. John Wiley & 
Sons. 
(237) Meng, X.-Y., Zhang, H.-X., Mezei, M., and Cui, M. (2011) Molecular docking: a powerful 
approach for structure-based drug discovery. Curr. Comput. Aided. Drug Des. 7, 146–57. 
(238) Huang, S.-Y., and Zou, X. (2010) Advances and Challenges in Protein-Ligand Docking. Int. J. Mol. 
Sci. 11, 3016–3034. 
(239) Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R., and Ferrin, T. E. (1982) A geometric 
approach to macromolecule-ligand interactions. J. Mol. Biol. 161, 269–88. 
(240) Gabb, H. A., Jackson, R. M., and Sternberg, M. J. (1997) Modelling protein docking using shape 
complementarity, electrostatics and biochemical information. J. Mol. Biol. 272, 106–20. 
(241) Miller, M. D., Kearsley, S. K., Underwood, D. J., and Sheridan, R. P. (1994) FLOG: a system to 
select “quasi-flexible” ligands complementary to a receptor of known three-dimensional structure. J. 




(242) Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., and Taylor, R. D. (2003) Improved 
protein-ligand docking using GOLD. Proteins 52, 609–23. 
(243) Rarey, M., Kramer, B., Lengauer, T., and Klebe, G. (1996) A fast flexible docking method using an 
incremental construction algorithm. J. Mol. Biol. 261, 470–89. 
(244) Morris, G. M., Goodsell, D. S., H., lliday, R.S., Huey, R., Hart, W. E., and Belew, R. K. and Olson, 
A. J. (1998) Au tomated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding 
Free Energy Function. J. Comput. Chem 19, 1639–1662. 
(245) Burkhard, P., Taylor, P., and Walkinshaw, M. D. (1998) An example of a protein ligand found by 
database mining: description of the docking method and its verification by a 2.3 A X-ray structure of a 
thrombin-ligand complex. J. Mol. Biol. 277, 449–66. 
(246) Plewczynski, D., Łaźniewski, M., Augustyniak, R., and Ginalski, K. (2011) Can we trust docking 
results? Evaluation of seven commonly used programs on PDBbind database. J. Comput. Chem. 32, 742–
55. 
(247) M. Sarwat, A. Ahmad, M. A. (2013) Stress Signaling in Plants: Genomics and Proteomics 
Perspective, Volume 1. Springer Science & Business Media. 
(248) Trott, O., and Olson, A. J. (2010) AutoDock Vina: improving the speed and accuracy of docking 
with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455–61. 
(249) Kufareva, I., Chen, Y.-C., Ilatovskiy, A. V, and Abagyan, R. (2012) Compound activity prediction 
using models of binding pockets or ligand properties in 3D. Curr. Top. Med. Chem. 12, 1869–82. 
(250) Oledzki, P. R., Laurie, A. T. R., and Jackson, R. M. (2004) Encyclopedia of Genetics, Genomics, 
Proteomics and Bioinformatics (Jorde, L. B., Little, P. F. R., Dunn, M. J., and Subramaniam, S., Eds.). 
John Wiley & Sons, Ltd, Chichester, UK. 
(251) Kriegenburg, F., Ellgaard, L., and Hartmann-Petersen, R. (2012) Molecular chaperones in targeting 
misfolded proteins for ubiquitin-dependent degradation. FEBS J. 279, 532–42. 
(252) Homeyer, N., and Gohlke, H. (2012) Free Energy Calculations by the Molecular Mechanics 
Poisson−Boltzmann Surface Area Method. Mol. Inform. 31, 114–122. 
(253) Bashford, D., and Case, D. A. (2000) Generalized born models of macromolecular solvation effects. 
Annu. Rev. Phys. Chem. 51, 129–52. 
(254) Tsui, V., and Case, D. A. (2000) Theory and applications of the generalized Born solvation model 
in macromolecular simulations. Biopolymers 56, 275–91. 
(255) Onufriev, A., Bashford, D., and Case, D. A. (2000) Modification of the Generalized Born Model 
Suitable for Macromolecules. J. Phys. Chem. B 104, 3712–3720. 
(256) Massova, I., and Kollman, P. A. (2007) Combined molecular mechanical and continuum solvent 




(257) Kollman, P. A., Massova, I., Reyes, C., Kuhn, B., Huo, S., Chong, L., Lee, M., Lee, T., Duan, Y., 
Wang, W., Donini, O., Cieplak, P., Srinivasan, J., Case, D. A., and Cheatham, T. E. (2000) Calculating 
Structures and Free Energies of Complex Molecules:  Combining Molecular Mechanics and Continuum 
Models. Acc. Chem. Res. 33, 889–897. 
(258) Hülsmann, Michael, Windt, K. (2007) Understanding Autonomous Cooperation and Control in 
Logistics: The Impact of Autonomy on Management, Information, Communication and Material Flow. 
Springer Science & Business Media. 
(259) Chang, C. A., McLaughlin, W. A., Baron, R., Wang, W., and McCammon, and J. A. (2008) 
Entropic contributions and the influence of the hydrophobic environment in promiscuous protein–protein 
association. 
(260) Ebadi, A., Razzaghi-Asl, N., Khoshneviszadeh, M., and Miri, R. (2013) Comparative amino acid 
decomposition analysis of potent type I p38α inhibitors. Daru 21, 41. 
(261) Lai, B., and Oostenbrink, C. (2012) Binding free energy, energy and entropy calculations using 
simple model systems. Theor. Chem. Acc. 131, 1272. 
(262) Lower, S. (2010) Gibbs Free Energy. http://www.chem1.com/acad/webtext/thermeq/TE4.html. 
(263) Hernández Alvarez, L., Naranjo Feliciano, D., Hernández González, J. E., Soares, R. O., Soares, R. 
de O., Barreto Gomes, D. E., and Pascutti, P. G. (2015) Insights into the Interactions of Fasciola hepatica 
Cathepsin L3 with a Substrate and Potential Novel Inhibitors through In Silico Approaches. PLoS Negl. 
Trop. Dis. 9, e0003759. 
(264) Lafont, V., Schaefer, M., Stote, R. H., Altschuh, D., and Dejaegere, A. (2007) Protein-protein 
recognition and interaction hot spots in an antigen-antibody complex: free energy decomposition 
identifies “efficient amino acids”. Proteins 67, 418–34. 
(265) Zoete, V., and Michielin, O. (2007) Comparison between computational alanine scanning and per-
residue binding free energy decomposition for protein-protein association using MM-GBSA: application 
to the TCR-p-MHC complex. Proteins 67, 1026–47. 
(266) Friedrich, B. M., Dziuba, N., Li, G., Endsley, M. a., Murray, J. L., and Ferguson, M. R. (2011) Host 
factors mediating HIV-1 replication. Virus Res. 161, 101–114. 
(267) Jonckheere, H., De Clercq, E., and Anné, J. (2000) Fidelity analysis of HIV-1 reverse transcriptase 
mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184. Eur. 
J. Biochem. 267, 2658–2665. 
(268) AmfAR. (2015) Statistics: Worldwide http://www.amfar.org/worldwide-aids-stats/#. 
(269) Abad, M. J., Bedoya, L. M., and Bermejo, P. (2007) HIV-Screening Strategies for the Discovery of 
Novel HIV-Inhibitors. 
(270) Jacobo-Molina, a, and Arnold, E. (1991) HIV reverse transcriptase structure-function relationships. 




(271) Usach, I., Melis, V., and Peris, J.-E. (2013) Non-nucleoside reverse transcriptase inhibitors : a 
review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. Int. AIDS Soc. 16, 1–15. 
(272) Barreca, M. L., Rao, A., De Luca, L., Iraci, N., Monforte, A.-M., Maga, G., De Clercq, E., 
Pannecouque, C., Balzarini, J., and Chimirri, A. (2007) Discovery of novel benzimidazolones as potent 
non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg. 
Med. Chem. Lett. 17, 1956–60. 
(273) Distinto, S., Esposito, F., Kirchmair, J., Cardia, M. C., Gaspari, M., Maccioni, E., Alcaro, S., Markt, 
P., Wolber, G., Zinzula, L., and Tramontano, E. (2012) Identification of HIV-1 reverse transcriptase dual 
inhibitors by a combined shape-, 2D-fingerprint- and pharmacophore-based virtual screening approach. 
Eur. J. Med. Chem. 50, 216–29. 
(274) Keller, P. a., Birch, C., Leach, S. P., Tyssen, D., and Griffith, R. (2003) Novel pharmacophore-
based methods reveal gossypol as a reverse transcriptase inhibitor. J. Mol. Graph. Model. 21, 365–373. 
(275) Penta, A., Ganguly, S., and Murugesan, S. (2013) Design and synthesis of tetrahydrophthalimide 
derivatives as inhibitors of HIV-1 reverse transcriptase. Org. Med. Chem. Lett. 3, 8. 
(276) Ren, J., Milton, J., Weaver, K. L., Short, S. A., Stuart, D. I., and Stammers, D. K. (2000) Structural 
Basis for the Resilience of Efavirenz (DMP-266) to Drug Resistance Mutations in HIV-1 Reverse 
Transcriptase. Structure 8, 1089–1094. 
(277) Zavodszky, M. I., Rohatgi, A., Van Voorst, J. R., Yan, H., and Kuhn, L. a. (2009) Scoring ligand 
similarity in structure-based virtual screening. J. Mol. Recognit. 22, 280–292. 
(278) Soliman, M. E. S. (2013) A hybrid structure/pharmacophore-based virtual screening approach to 
design potential leads: A computer-aided design of South African HIV-1 subtype C protease inhibitors. 
Drug Dev. Res. 74, 283–295. 
(279) Gu, W. (2014) Impact of Virtual Screening on HIV Reverse Transcriptase Inhibitor Discovery. 
Jacobs Publ. 1, 14–15. 
(280) Giovanni. (2013) Virtual screening strategies in drug discovery: A critical review. Curr. Med. 
Chem. 20, 2839–2860. 
(281) Shoichet, B. K., McGovern, S. L., Wei, B., and Irwin, J. J. (2002) Lead discovery using molecular 
docking. Curr. Opin. Chem. Biol. 6, 439–446. 
(282) Hanwell, M. D., Curtis, D. E., Lonie, D. C., Vandermeerschd, T., Zurek, E., and Hutchison, G. R. 
(2012) Avogadro: An advanced semantic chemical editor, visualization, and analysis platform. J. 
Cheminform. 4, 1–17. 
(283) Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and 





(284) D.A. Case, J.T. Berryman, R.M. Betz, D.S. Cerutti, T.E. Cheatham, III, T.A. Darden, R.E. Duke, 
T.J. Giese, H. Gohlke, A.W. Goetz, N. Homeyer, S. Izadi, P. Janowski, J. Kaus, A. Kovalenko, T.S. Lee, 
S. LeGrand, P. Li, T. Luchko, R. Luo, B. Madej, K.M. Merz, D. M. Y. and P. A. K. (2015) Amber14. 
(285) Götz, A. W., Williamson, M. J., Xu, D., Poole, D., Le Grand, S., and Walker, R. C. (2012) Routine 
microsecond molecular dynamics simulations with AMBER on GPUs. 1. generalized born. J. Chem. 
Theory Comput. 8, 1542–1555. 
(286) Duan, Y., Wu, C., Chowdhury, S. S., Lee, M. C., Xiong, G., Zhang, W., Yang, R., Cieplak, P., Luo, 
R., Lee, T., Caldwell, J., Wang, J., and Kollman, P. (2003) A point-charge force field for molecular 
mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J. 
Comput. Chem. 24, 1999–2012. 
(287) Maria Antony J.E., A. D. M. . (2012) Virtual screening and lead optimisation to identify novel 
inhibitors for HDAC-8 58. 
(288) Harvey, M. J., and De Fabritiis, G. (2009) An implementation of the smooth particle-mesh Ewald 
(PME) method on GPU hardware. J. Chem. Theory Comput. 5, 2371–2377. 
(289) Wu, X., and Brooks, B. R. (2003) Self-guided Langevin dynamics simulation method. Chem. Phys. 
Lett. 381, 512–518. 
(290) Kräutler, V., Van Gunsteren, W. F., and Hünenberger, P. H. (2001) A fast SHAKE algorithm to 
solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. 
Chem. 22, 501–508. 
(291) Berendsen et al. (1984) Molecular dynamics with coupling to an external bath. J. Chem. Phys. 81, 
3684–3690. 
(292) Dallakyan, S. (2010) MGLTools Website - Welcome — MGLTools. http://mgltools.scripps.edu/. 
(293) Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., Olson, A. J., 
and Al, M. E. T. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical 
binding free energy function. J. Comput. Chem. 19, 1639–1662. 
(294) Hou, T., Wang, J., Li, Y., and Wang, W. (2011) Assessing the performance of the molecular 
mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area 
methods. II. The accuracy of ranking poses generated from docking. J. Comput. Chem. 32, 866–77. 
(295) Lyne, P. D., Lamb, M. L., and Saeh, J. C. (2006) Accurate Prediction of the Relative Potencies of 
Members of a Series of Kinase Inhibitors Using Molecular Docking and MM-GBSA Scoring. J. Med. 
Chem. 49, 4805–4808. 
(296) Koes, D. R., and Camacho, C. J. (2012) ZINCPharmer: Pharmacophore search of the ZINC 
database. Nucleic Acids Res. 40, 409–414. 
(297) Irwin, J. J., and Shoichet, B. K. ZINC--a free database of commercially available compounds for 




(298) Manuscript, A. (2012) NIH Public Access. Changes 29, 997–1003. 
(299) Kroeger Smith, M. B., Rouzer, C. A., Taneyhill, L. A., Smith, N. A., Hughes, S. H., Boyer, P. L., 
Janssen, P. A., Moereels, H., Koymans, L., and Arnold, E. (1995) Molecular modeling studies of HIV-1 
reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug 
placement and activity. Protein Sci. 4, 2203–22. 
(300) Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S., Hellmig, B., Woolf, D. J., 
Debouck, C., and Harrison, S. C. (1995) The structure of unliganded reverse transcriptase from the human 
immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 92, 1222–1226. 
(301) Das, K., Martinez, S. E., Bandwar, R. P., and Arnold, E. (2014) Structures of HIV-1 RT-RNA/DNA 
ternary complexes with dATP and nevirapine reveal conformational flexibility of RNA/DNA: Insights 
into requirements for RNase H cleavage. Nucleic Acids Res. 42, 8125–8137. 
(302) Madrid, M., Jacobo-Molina, A., Ding, J., and Arnold, E. (1999) Major subdomain rearrangement in 
HIV-1 reverse transcriptase simulated by molecular dynamics. Proteins Struct. Funct. Genet. 
(303) Temiz, N. A., and Bahar, I. (2002) Inhibitor binding alters the directions of domain motions in 
HIV-1 reverse transcriptase. Proteins Struct. Funct. Genet. 
(304) The Henry J. Kaiser Foundation. (2015) The Global HIV/AIDS Epidemic. http://kff.org/global-
health-policy/fact-sheet/the-global-hivaids-epidemic/. 
(305) Vento, S., Renzini, C., Casali, F., Ghironzi, G., and Concia, E. (1998) Highly active antiretroviral 
therapy. Lancet 351, 1058; author reply 1058–1059. 
(306) Monforte, A., Lepri, A., Rezza, G., Pezzotti, P., Antinori, a, Phillips, an, Angarano, G., Colangeli, 
V., De Luca, a, Ippolito, G., Caggese, L., Soscia, F., Filice, G., Gritti, F., Narciso, P., Tirelli, U., Moroni, 
M., and Grp, I. S. (2000) Insights into the reasons for discontinuation of the first highly active 
antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients 499–507. 
(307) Bhakat et al. (2014) An integrated molecular dynamics, principal component analysis and residue 
interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase 
resistance to lamivudine. Mol. Biosyst. 10, 2215–28. 
(308) Moonsamy, S., Bhakat, S., and Soliman, M. E. S. (2014) Dynamic features of apo and bound HIV-
Nef protein reveal the anti-HIV dimerization inhibition mechanism. J. Recept. Signal Transduct. 9893, 1–
11. 
(309) Geller et al. (2012) Broad action of Hsp90 as a host chaperone required for viral replication. 
Biochim. Biophys. Acta-Molecular Cell Res. 1823, 698–706. 
(310) Pearl, L. H., and Prodromou, C. (2006) Structure and mechanism of the Hsp90 molecular chaperone 
machinery, in Annual Review of Biochemistry, pp 271–294. Annual Reviews, Palo Alto. 
(311) Krukenberg, K. A., Street, T. O., Lavery, L. A., and Agard, D. A. (2011) Conformational dynamics 




(312) Chadli, A., Bouhouche, I., Sullivan, W., Stensgard, B., McMahon, N., Catelli, M. G., and Toft, D. 
O. (2000) Dimerization and N-terminal domain proximity underlie the function of the molecular 
chaperone heat shock protein 90. Proc. Natl. Acad. Sci. U. S. A. 97, 12524–12529. 
(313) Whitesell, L., and Lindquist, S. L. (2005) HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 
5, 761–72. 
(314) Kang, B. H., Plescia, J., Dohi, T., Rosa, J., Doxsey, S. J., and Altieri, D. C. (2007) Regulation of 
tumor cell mitochondrial Homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131, 257–
270. 
(315) McClellan, A. J., Xia, Y., Deutschbauer, A. M., Davis, R. W., Gerstein, M., and Frydman, J. (2007) 
Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 
131, 121–135. 
(316) Drysdale, M. J., Brough, P. A., Massey, A., Jensen, M. R., and Schoepfer, J. (2006) Targeting 
Hsp90 for the treatment of cancer. Curr. Opin. Drug Discov. Devel. 9, 483–495. 
(317) Neckers, L., and Workman, P. (2012) Hsp90 molecular chaperone inhibitors: Are we there yet? 
Clin. Cancer Res. 18, 64–76. 
(318) Soga, S., Akinaga, S., and Shiotsu, Y. (2013) Hsp90 inhibitors as anti-cancer agents, from basic 
discoveries to clinical development. Curr. Pharm. Des. 19, 366–76. 
(319) Kumalo, H. M., Bhakat, S., and Soliman, M. E. (2015) Heat-Shock Protein 90 (Hsp90) as 
Anticancer Target for Drug Discovery: An Ample Computational Perspective. Chem. Biol. Drug Des. 
n/a–n/a. 
(320) Vozzolo, L., Loh, B., Gane, P. J., Tribak, M., Zhou, L., Anderson, I., Nyakatura, E., Jenner, R. G., 
Selwood, D., and Fassati, A. (2010) Gyrase B Inhibitor Impairs HIV-1 Replication by Targeting Hsp90 
and the Capsid Protein. J. Biol. Chem. 285, 39314–39328. 
(321) Benkovic & Hammes-Schiffer. (2003) A perspective on enzyme catalysis. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12947189. Science 301, 1196–1202. 
(322) Dixit, A., and Verkhivker, G. M. (2012) Probing molecular mechanisms of the Hsp90 chaperone: 
biophysical modeling identifies key regulators of functional dynamics. PLoS One 7, e37605. 
(323) Verkhivker, G. M., Dixit, A., Morra, G., and Colombo, G. (2009) Structural and computational 
biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-
based inhibitor design. Curr. Top. Med. Chem. 9, 1369–85. 
(324) Connor, J. H., McKenzie, M. O., Parks, G. D., and Lyles, D. S. (2007) Antiviral activity and RNA 
polyinerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 362, 
109–119. 
(325) Sidera, K., and Patsavoudi, E. (2014) HSP90 inhibitors: current development and potential in 




(326) Bonavia, A., Franti, M., Pusateri Keaney, E., Kuhen, K., Seepersaud, M., Radetich, B., Shao, J., 
Honda, A., Dewhurst, J., Balabanis, K., Monroe, J., Wolff, K., Osborne, C., Lanieri, L., Hoffmaster, K., 
Amin, J., Markovits, J., Broome, M., Skuba, E., Cornella-Taracido, I., Joberty, G., Bouwmeester, T., 
Hamann, L., Tallarico, J. A., Tommasi, R., Compton, T., and Bushell, S. M. (2011) Identification of 
broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against 
respiratory syncytial virus (RSV). Proc. Natl. Acad. Sci. U. S. A. 108, 6739–44. 
(327) Kowalczyk et al. (2005) Heat shock protein and heat shock factor 1 expression and localization in 
vaccinia virus infected human monocyte derived macrophages. J. Inflamm. (Lond). 2, 12. 
(328) Weeks, S. A., Shield, W. P., Sahi, C., Craig, E. A., Rospert, S., and Miller, D. J. (2010) A Targeted 
Analysis of Cellular Chaperones Reveals Contrasting Roles for Heat Shock Protein 70 in Flock House 
Virus RNA Replication. J. Virol. 84, 330–339. 
(329) Nakagawa, S., Umehara, T., Matsuda, C., Kuge, S., Sudoh, M., and Kohara, M. (2007) Hsp90 
inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. 
Commun. 353, 882–888. 
(330) Ujino, S., Shimotohno, K., and Takaku, H. (2007) 17-AAG, an Hsp90 Inhibitor, Suppress Hepatitis 
C Virus (HCV) Replication. Antiviral Res. 74, A62–A63. 
(331) Castorena, K. M., Weeks, S. A., Stapleford, K. A., Cadwallader, A. M., and Miller, D. J. (2007) A 
functional heat shock protein 90 chaperone is essential for efficient flock house virus RNA polymerase 
synthesis in Drosophila cells. J. Virol. 81, 8412–8420. 
(332) Kim, M.-G., Moon, J.-S., Kim, E.-J., Lee, S.-H., and Oh, J.-W. (2012) Destabilization of PDK1 by 
Hsp90 inactivation suppresses hepatitis C virus replication through inhibition of PRK2-mediated viral 
RNA polymerase phosphorylation. Biochem. Biophys. Res. Commun. 421, 112–118. 
(333) Zhong, M., Zheng, K., Chen, M., Xiang, Y., Jin, F., Ma, K., Qiu, X., Wang, Q., Peng, T., Kitazato, 
K., and Wang, Y. (2014) Heat-shock protein 90 promotes nuclear transport of herpes simplex virus 1 
capsid protein by interacting with acetylated tubulin. PLoS One 9, e99425–e99425. 
(334) Carvalho et al. (2014) Challenges in computational studies of enzyme structure, function and 
dynamics. J. Mol. Graph. Model. 54, 62–79. 
(335) Lindorff-Larsen, K., Piana, S., Dror, R. O., and Shaw, D. E. (2011) How Fast-Folding Proteins 
Fold. Science (80-. ). 334, 517–520. 
(336) Beck, D. A. C., and Daggett, V. (2004) Methods for molecular dynamics simulations of protein 
folding/unfolding in solution. Methods 34, 112–20. 
(337) Gsponer, J., and Caflisch, A. (2002) Molecular dynamics simulations of protein folding from the 
transition state. Proc. Natl. Acad. Sci. U. S. A. 99, 6719–6724. 
(338) Swope, W. C., and Pitera, J. W. (2004) Describing Protein Folding Kinetics by Molecular 




(339) Durrant, J. D., and McCammon, J. A. (2011) Molecular dynamics simulations and drug discovery. 
BMC Biol. 9, 71. 
(340) Et, W. (2013) Molecular dynamics simulations of wild type and mutants of human complement 
receptor 2 complexed with C3d. Phys. Chem. Chem. Phys. 15, 1241–1251. 
(341) Ruiz-Pernia, J. J., Silla, E., and Tunon, I. (2007) Enzymatic Effect on Reactant and Transition 
States. Chalcone Isomerase. J. Am. Chem. Soc. 129 , 9117–9124. 
(342) Falconi, M., Biocca, S., Novelli, G., and Desideri, A. (2007) Molecular dynamics simulation of 
human LOX-1 provides an explanation for the lack of OxLDL binding to the Trp150Ala mutant. BMC 
Struct. Biol. 7, 73. 
(343) Ali, M. M. U., Roe, S. M., Vaughan, C. K., Meyer, P., Panaretou, B., Piper, P. W., Prodromou, C., 
and Pearl, L. H. (2006) Crystal structure of an Hsp90-nucleotide-p23/Sba1 closed chaperone complex. 
Nature 440, 1013–1017. 
(344) Harris, S. F., Shiau, A. K., and Agard, D. a. (2004) The Crystal Structure of the Carboxy-Terminal 
Dimerization Domain of htpG, the Escherichia coli Hsp90, Reveals a Potential Substrate Binding Site. 
Structure 12, 1087–1097. 
(345) Moonsamy, S. and Soliman, M. . (2014) Computer-aided perspective for the design of flexible HIV 
non-nucleoside reverse transcriptase inhibitors (NNRTIs): de-novo design, virtual screening and 
molecular dynamics simulations. Lett. Drug Des. Discov. 513–524. 
(346) Moonsamy, S., and Soliman, M. E. S. (2014) Dual acting HIV inhibitors: Integrated rational in 
silico design strategy. Med. Chem. Res. 23, 682–689. 
(347) Jorgensen et. (1983) Comparsion of simple potential functions for simulating liquid water. J Chem 
Phys 79, 926–35. 
(348) Greenidge, P. a, Kramer, C., Mozziconacci, J.-C., and Sherman, W. (2014) Improving Docking 
Results via Reranking of Ensembles of Ligand Poses in Multiple X-ray Protein Conformations with MM-
GBSA. J. Chem. Inf. Model. 
(349) Roe, D. R., and Cheatham  III, T. E. (2013) PTRAJ and CPPTRAJ: Software for Processing and 
Analysis of Molecular Dynamics Trajectory Data. J. Chem. Theory Comput. 9, 3084–3095. 
(350) Kasahara et al. (2014) A novel approach of dynamic cross correlation analysis on molecular 
dynamics simulations and its application to Ets1 dimer-DNA complex. PLoS One 9, e112419. 
(351) Laskowski., A. C. W. and R. A. (2003) LIGPLOT v.4.5.3. - Operating manual. 
http://www.ebi.ac.uk/thornton-srv/software/LIGPLOT/manual/. 
(352) Sattin, S., Tao, J., Vettoretti, G., Moroni, E., Pennati, M., Lopergolo, A., Morelli, L., Bugatti, A., 
Zuehlke, A., Moses, M., Prince, T., Kijima, T., Beebe, K., Rusnati, M., Neckers, L., Zaffaroni, N., Agard, 
D. A., Bernardi, A., and Colombo, G. (2015) Activation of Hsp90 Enzymatic Activity and 




(353) OriginLab - Origin and OriginPro - Data Analysis and Graphing Software. 
http://www.originlab.com/. 
(354) Chen, H.-F., Fan, B.-T., Zhao, C.-Y., Xie, L., Zhao, C.-H., Zhou, T., Lee, K.-H., and Allaway, G. 
(2005) Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3’,4'-di-O-(S)-
camphanoyl-(+)-cis-khellactone (DCK) analogs. J. Comput. Aided. Mol. Des. 19, 243–58. 
(355) Jayatilleke, P. R., Nair, A. C., Zauhar, R., and Welsh, W. J. (2000) Computational studies on HIV-1 
protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 
3D-QSAR CoMFA models. J. Med. Chem. 43, 4446–51. 
(356) Nair, A. C., Jayatilleke, P., Wang, X., Miertus, S., and Welsh, W. J. (2002) Computational Studies 
on Tetrahydropyrimidine-2-one HIV-1 Protease Inhibitors:  Improving Three-Dimensional Quantitative 
Structure−Activity Relationship Comparative Molecular Field Analysis Models by Inclusion of 
Calculated Inhibitor- and Receptor-Based P. J. Med. Chem. 45, 973–983. 
(357) Nair, A. C., Bonin, I., Tossi, A., Welsh, W. J., and Miertus, S. (2002) Computational studies of the 
resistance patterns of mutant HIV-1 aspartic proteases towards ABT-538 (ritonavir) and design of new 
derivatives. J. Mol. Graph. Model. 21, 171–179. 
(358) Nair, A. C., Jayatilleke, P., Wang, X., Miertus, S., and Welsh, W. J. (2002) Computational studies 
on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative 
structure-activity relationship comparative molecular field analysis models by inclusion of calculated 
inhibitor- and receptor-based pr. J. Med. Chem. 45, 973–83. 
(359) Nunthaboot, N. (2015) Computational Studies of HIV-1 Integrase and its Inhibitors. Curr. Comput. 






Accepted article  
 
Per-residue energy decomposition (PRED) pharmacophore model to enhance virtual 
screening (VS) in drug discovery: A case study for identification of Reverse transcriptase 
(RT) inhibitors as potential Anti-HIV agents. 
Favourite N. Cele, Ramesh Muthusamy and Mahmoud E.S Soliman*. 
Molecular Modelling and Drug Design Research Group, School of Health Sciences, University of 
KwaZulu-Natal, Westville, Durban 4001, South Africa 
* Corresponding author: Mahmoud. E.S. Soliman; Email: soliman@ukzn.ac.za 
Telephone: +27 031 260 7413, Fax: +27 031 260 7792 












































A novel virtual screening (VS) approach is implemented herein, which is a further improvement of our 
previously published “target-bound pharmacophore modeling approach”.  The generated pharmacophore 
library is based only on highly contributing amino acid residues (HCAAR), instead of arbitrary 
pharmacophores, which is most commonly used in the conventional approaches in literature. HCAAR 
were distinguished based on free binding energy (FBE) contributions obtained from calculation from 
molecular dynamics (MD) simulations. To the best of our knowledge; this is the first attempt in the 
literature using such an approach; previous approaches rely on the docking score (DS) to generate energy-
based pharmacophore models.  However, DS are reportedly unreliable. Thus we present a model for a 
per-residue energy decomposition (PRED), constructed from MD simulations ensembles generating a 
more trustworthy pharmacophore model which can be applied in drug discovery workflow. This work is 
aimed at introducing a more rational approach to drug design field, rather than comparing the validity of 
this approach against those previously reported. We recommend additional computational and 
experimental work to further validate this approach. This approach was used to screen for potential 
reverse transcriptase (RT) inhibitors using the pharmacophoric features of compound GSK952. The 
complex was subjected to docking and thereafter MD simulation confirmed the stability of the system. 
Experimentally determined inhibitors with known HIV-RT inhibitory activity were used to validate the 
protocol. Two potential hits ZINC46849657 and ZINC54359621 showed a significant potential with 
regards to FBE. Reported results obtained from this work confirm that this new approach is favorable to 
the future of drug design industry.  
Keywords: HIV-1; Reverse Transcriptase; GSK952; Molecular Dynamic simulations; Pharmacophore 












Human immunodeficiency virus (HIV) infection is the leading cause of death across the globe266. There 
are two strains of HIV, namely, HIV-1 and HIV-2. HIV-1 is the most infectious and prevalent globally267. 
Worldwide statistics by the American foundation for AIDS Research (amfAR) reported that sub-Saharan 
African is the most affected region, with approximately 70% of adults and 91% of children are HIV 
positive268.  
HIV-1 RT is currently an essential target for the United State Food and Drug Administration (FDA) 
approved HIV-1 therapy2 and a prominent target of many approved anti-HIV drugs that are key 
components of Highly Active Anti-Retroviral Therapies (HAART)43. The HIV-1 RT enzyme catalyzes 
the conversion of viral RNA into cDNA which enters the host nucleus and it is incorporated into host 
chromosomal DNA of the host cell by the enzyme integrase (IN) enzyme269. It is the sole viral enzyme 
required for the catalytic formation of cDNA generated from viral RNA hence plays a central role in HIV 
replication270 making it a prime target for HIV-1 therapy.  HIV-1 RT is a heterodimer consisting of two 
subunits; a p66 subunit (DNA polymerization site and RNase H active site) responsible for the replication 
of the single stranded RNA genome found in virions into the double-stranded DNA; and a p51 subunit 
which is responsible for the proper folding of p66 rather than the catalytic subunit 12 (Figure 1). 
 
Figure 1: Ribbon representation of the HIV-1 RT-GSK952 complex (PDB code 2YNI150) with finger 
(blue), palm (magenta), thumb (cyan), connection (forest green) and RNase H (orange red) of p66 subunit 
and GSK952 (green). 
 HIV-1 RT does not possess any proofreading activity. Thus, DNA synthesis prone to errors can be 




Etravirine (ETR) and rilpivirine (RPV) are the most recent non-nucleoside reverse transcriptase inhibitors 
(NNRTIs) resistant to which mutated RT viruses are resistant to271. To date, NNRTIs resistance still poses 
a challenge with regards to NNRTIs therapy. Thus, there is a clear need for the discovery of new drugs 
with greater resistance profiles capable of inhibiting HIV-I RT mutated viruses. Numerous studies have 
made a significant attempts in the discovery of new potent NNRTIs using a pharmacophore model 
approaches272–274.  
The potential anti-HIV drug needs to be effective against resistant strains. The present study looked at 
GSK952, a newly discovered NNRTI. The crystal structure (PDB 2YNI)150 of the catalytic domain of 
HIV-1 RT enzyme bound to GSK952 is available. GSK952 shows high potency against the mutated 
Y188L strain as well as the mutated Y188C and K103N strains. Previous work on this compound 
confirmed it has a good inhibitory activity against HIV-1 RT, including the mutated viral Y188L HIV-1 
RT strains150. It exhibited a high antiviral profiles when compared to a group of compounds sharing a 
common imidazole-amide biarylether scaffold150. It possesses a linear arrangement of a hydrogen bond 
acceptors (C=O) and donors (NH), which are required for binding to HIV-1 RT and to form hydrogen 
bonds with residues in the active site including K101, K103, and P236275. GSK952 forms hydrogen bonds 
with NH and C=O groups (S1), which are positioned along the protein backbone rather than the side 




Figure 2: The 2D structure of ligand GSK952 used to generate the pharmacophore model. 
 
In this mutation the side chain of K103 is tilted away from the inhibitor due to the mutation of the wild 
type to Asn103150. GSK952 (Figure 2) has reveals an extraordinary antiviral activity against a wide range 
of NNRTI-resistant viruses150 and forms favorable pharmacokinetic profiles across multiple species. We 
believe it has a great potential and deserves further exploration. Thus it is an ideal compound for the 





Computational tools and capability escalation have lead VS to become a routine method in 
pharmaceutical drug discovery277. Numerous computational screening tools are accessible for mining of 
inhibitors with properties of interest278.VS is one of the most trusted and convenient tools in drug design. 
Literature confirms its reliability in the discovery of novel HIV-1 RT inhibitors through VS279. VS is 
either ligand-based or structure based46. Structure-based virtual screening (SBVS) uses the 3D structure of 
the receptor to search for potential ligands59. Ligand-based VS (LBVS) also known as pharmacophore-
based VS explores features or properties of known bioactive ligands and searches for compounds with 
similarities280 and favorable features of a known active are used to build a pharmacophore model. 
Amongst other models pharmacophore searches are finest at discovering a range of chemical structures 
with feasible features hence the principal method for the initial selection of compounds48. Ligand-based 
pharmacophore approaches generates libraries based on a set of known ligands illustrative of crucial 
interactions between the ligands and a particular target49. Whereas structure-based pharmacophore models 
are based on the knowledge of the 3D structure of the target50. Numerous studies have combined LBVS 
and SBVS with the aim of improving the VS process51–53. A number of studies have implemented on 
improving VS and pharmacophore model54–58. A previous study proposed a target-bound ensemble 
generated pharmacophore model to further improve pharmacophore-based VS. It has been confirmed that 
a target-bound pharmacophore-based VS is a more rational approach59. Yet to this date, general standards 
for VS with regards to method evaluation are insufficient. The aim of this work is to identify more 
potential NNRTIs by exploiting the structural features of GSK952 using a pharmacophore model. 
We propose implementing an approach aims at improving and refining the current pharmacophore 
approach. This approach is centered on the type of interactions witnessed at a molecular level which 
includes hydrogen bonding, charge and hydrophobic interactions60. This approach will search for 
compounds that interact with the highly contributing residues based on the FBE.  
In this study we performed MD simulations, pharmacophore-based VS and PRED analysis for residues 
with the greatest FBE contributions. VS depends primarily on docking calculations although results based 
exclusively on docking calculations are rather questionable281. To test the validity of our proposed 
approach, we applied the same docking procedure to a set of experimentally determined inhibitors with 
known HIV-1RT inhibition activity. In our approach we intend to unshackle the limitations of previous 
approaches, such as using non-crucial residues, which retrieves a large number of hits with assumed 
activity. In an attempt to enhance the accuracy of the pharmacophore model we only selected HCAAR. A 
target-bound ensemble was employed in the current study, in the hope of implementing a better approach. 




methods use pharmacophore maps created without considering the energy contributions of interacting 
residues. Only potential pharmacophore moieties were considered thus, the library of potential 
compounds generated is more concise and direct. In our approach the energy-based pharmacophore map 
is generated using the FBE calculated from MD, which is a more reliable approach, compared to the 
conventional approach using DC. We believe this approach will be of a greater advantage to the 
conventional approach due to these key factors highlighted above. The refinement of the method 
proposed in this study could be implemented as a potential tool for medicinal chemists in the search for 



























2. Computational methodology 
2.1 The computational tools implemented in this study are represented in the workflow in Figure 3.  
 
Figure 3: A schematic representation of the VS workflow used in the current study 
 
2.2 A diagrammatic representation of the pharmacophore model used in this study is shown presented in 
Figure 4. The residues with the highest energy contributions are numbered and ranked from 1-6, with one 




select the corresponding pharmacophore moieties on the ligand to generate a pharmacophore model used 
to screen a database for potential hit compounds. 
 
  
Figure 4: A diagrammatic representation of the pharmacophore model, a) PRED contributions, b) 2D 
ligand interaction plot and c) Pharmacophore features responsible for FBE contributions. 
 




The crystal structure of HIV-1 RT-GSK952 complex was obtained from Protein Data Base (PDB: 
2YNI150). The steepest decent method and MMFF94S force field in Avogadro software282 was used to 
minimize conformation HIV-1 RT-GSK952 complex. The crystal structure was opened on UCSF 
chimera283 to delete chain B and solvents (H2O, MG, TAR). GSK952 was selected and deleted. GSK952 
was prepared by adding hydrogen. The ligand was prepared using Antechamber and tLeap of Amber14284 
were used to optimize both HIV-1 RT (enzyme) and GSK952 (ligand) respectively to ensure all 
parameters are present for MD simulations. Topology files generated were submitted for MD simulation. 
2.3 Molecular dynamic simulations 
Solvation of MD simulations285 was performed on HIV-1 RT-GSK952 using the GPU version of the 
PMEMD engine integrated with Amber14284. Leap module in Amber 14284 was used to add hydrogen 
atoms to the proteins. The standard Amber force field was employed to treat the receptor for bioorganic 
systems (ff99sb)286. A box of equilibrated TIP3P287 water molecules were arranged around the receptor at 
a distance of 10Å distance around the enzyme and Cl-  ions were  added to neutralise the systems. Cubic 
periodic boundary conditions were employed and particle- mesh Ewald method288 applied in Amber12 
was used to treat the long-range electrostatic interactions with non-bonding at 2 fs integration step. The 
initial minimization of the system was carried out using the steepest descent method for 1000 steps. A 
canonical ensemble (NVT) MD was carried out for 50 ps, during which the system was progressively 
heated up from 0 to 300 K by means of a Langevin thermostat289.The system was then equilibrated at 300 
K under 1 atm pressure while preserving the force constants on the restrained solute. Throughout all MD 
simulations the SHAKE algorithm290 was employed on all covalently bonded atoms to a hydrogen atom. 
A production run was achieved, with no restraints, for 5 ns in an isothermal isobaric (NPT) ensemble 
employing a Berendsen barostat.291 Trajectory exploration including the RMSD, RMSF, and Rg were 
carried out using PTRAJ and CPPTRAJ modules applied in AMBER14284. 
The trajectory was saved every 1 ps and examined every 1 ps using the PTRAJ module applied in 
Amber14284. The structure was visualized using graphical user interface of UCSF Chimera package283. 
Data was plotted using the GUI of Microcal Origin data analysis software version6 (www.originlab.com). 
2.5 Molecular docking.  
AutoDock Vina was used for docking calculation248. Geister partial chargers were allocated during 
docking. AutoDock Graphical user interface provided by MGL tools were used to outline the AutoDock 
atom types292. The docked conformations were obtained using the Lamarckian Genetic Algorithm293. The 




including the highest contributing Leu100, Lys102, Lys103, Val106, Try188 and Phe227 residues. The 
classification of the compounds was in accordance with their DS in a descending order. 
 
Free binding energy calculations. 
The FBE of the docked complexes was calculated to support the docking calculations and to predict the 
binding efficiencies of the HIV-1 RT against the targets. The FBE predictions are performed using 
MMPBSA that incorporates equation (1)294 and MMGBSA method that incorporates equation (2)295. 
   ∆Gbind = Gcomplex- Gprotein- Gligand            (1) 
                =  ∆EMM + ∆GPB+ ∆Gnon-polar - TΔS 
 
    ∆Gbind = ∆EMM + ∆Gsolv + ∆GSA      (2) 
  
Here, ΔEMM is the difference between the minimized energies of the HIV-1RT-GSK952 complex and the 
total energies of the HIV-1 RT and HIV-1 RT inhibitor including the electrostatic and the van der Waals 
energies, TΔS is the change in entropy of the ligand binding conformations, ΔGsolv is the difference in the 
P/GBSA solvation energies of the HIV-1 RT- GSK952 complex and the sum of the solvation energies of 
the HIV-1 RT and HIV-1 RT inhibitor, ΔGSA is the difference in the surface area energies for the HIV-RT 
enzymes and HIV-1 RT inhibitor. Both MMPBSA and MMGBSA methods have been realized to ensure 
the accurate ranking of inhibitors based on their FBE and hence can serve as a powerful tool in the drug 
design research. 
3. Results and discussion 
3.1 PRED-pharmacophore model. 
The pharmacophore model exploits both the structural features of the proteins as well as the chemical 
features ligands. To generate a PRED based pharmacophore model, PRED decomposition was computed 
from MMPBSA calculations after 5ns MD simulations of the (2YNI-GSK952) complex. Residues 
Leu100, Lys102, Lys103, Val106, Try188 and Phe227 were found to be highest contributing residues that 
interact with the ligands (S2). The pharmacophoric features of the ligands hydrophobic interaction, 
hydrogen acceptor and hydrogen bond interactions (HPI, HA and HBI respectively) were found to 
interact with Leu100, Lys102, Val106, Try188, Lys103, Phe227 and Lys103 respectively. These ligand 




Further the PRED-based pharmacophore model (S3) was used to screen the ZINC database297 for 
compounds with similar features to obtain the novel hits. Additionally, a further selection criterion was 
implemented when screening ZincPharmer database. 788 hits were obtained from the ZINC database. 
3.2 Molecular docking 
All 788 hits were docked into the crystal structure (2YNI) to assess their chemical and physical 
feasibility. Thus the only with the correct pose and physical properties were selected for further 
consideration. This provided valuable insights into the nature of the binding site and the key ligand-
protein interactions that are responsible for the molecular recognition and served as a validation step in 
the proposed workflow. A set of four compounds with experimentally determined activity (IC50 values) 
was selected to further validate our findings. These four compounds were docked into the crystal structure 
of 2YNI as described above in section 2.5. Calculated DS were correlated against the inhibitors 
experimentally determined IC50 values (Table 1). DS are in correlation  
(R2 = 0.62128) (Figure 5) with the IC50 values. The comparison by means of correlation serves as an 
additional validation step and add robustness and validity to the docking protocol used in the current 
study. After the validation, molecular docking was carried out for all 788 hits. 








1 3M8Q -8.8 0.6 
2 2BAN -8.4 1 
3 3IRX -9.2 1 






Figure 5: Validation of molecular docking: DS vs IC50 
The top 10 compounds with the highest docking scores were selected from the library of 788 hits. The 
docking scores for the top 10 compounds ranged from -11.5 to -12.4 kcal/mol (Table 2). It should be 
noted that there is not much difference in the binding energy of the top 10 compounds with the rough 
range of 0.9 kcal/mol. Hit compounds were found to be more stable due to conservation of vital 















Table 2: Representation of the top 10 compounds displaying 2D shapes, HBD, HBA, xlogP, MW and 













































































































































































































































































































































































It is of high importance to consider residues that are directly accountable for the efficacy of HIV-1 RT 
when evaluating whether the molecules bind strongly with HIV-1 RT. This will ensure effective 
inhibition. Lig-plot analysis is best suited for displaying the 2D interaction between the ligand and the 
residue contributing to the ligand binding. Lig-plot shows the interacting residues with Leu100, Lys102, 
Lys103, Val106, Tyr188, and Phe227 with the highest FBE contributing to the ligand binding. Leu100, 
Lys102, Val106, Phe227, Pro229 and Y188 have hydrophobic interactions whereas Lys103 displays a 
hydrogen interaction with the inhibitor (Figure 4). The PRED calculations presented in this study are 
valuable tools that can be employed to highlight the most significant residues involved in the binding of 
the inhibitor serve as a guide to design drug candidates against HIV-RT. 
The FDA-approved anti-HIV drugs were omitted throughout the entire screening process, this is to 
guarantee the design of compound libraries based on novel structural scaffolds. Such findings affirms the 
refined pharmacophore approach adopted in this work, rendering the suggested concept could be secure 
and dependable enough for the mining of novel drug candidates against the enzyme of interest.  We 
believe the methodology in this current work can be applied to more biological drug targets with 




Molecular dynamic simulations and MMPBSA calculations. 
As previously mentioned, docking alone cannot provide reliable results. Hence it is of high importance to 
correlate docking results with MD simulations. MD simulation (5ns) was performed on the top 10-
screened hits from the molecular docking to confirm the change in mobility resulting from the binding of 
each hit to HIV-1 RT. Common MD-type force fields were employed to evaluate and rescore the docked 
complexes, this will lead to more accurate estimates of the binding affinities. All the free energy 
components are representative of averaged values over the 5 ns MD simulations calculated using the 
MM/PBSA approach shown below in Table 3. Amongst the top 10, ZINC54359621 and ZINC46849657 
resulted with the highest FBE. The total calculated FBE (∆Gbind) of GSK952 against HIV-1 RT protein is 
-58.8 kcal/mol compared to -58.5 kcal/mol and -59.0 kcal/mol of ZINC46849657 and, ZINC54359621 
respectively.  These findings are more reliable than the energy contributions obtained from the docking 
calculations. It was also observed that the ∆EvdW of ZINC54359621 and ZINC46849657 was higher 
(Table 3, Figure 6), which is advantageous and a contributing factor towards the high binding affinity298. 
Electrostatic forces contribute to inhibitor molecules to gain binding energy299. ZINC54359621 and 
ZINC46849657 electrostatic interactions are similar to that of GSK952, which explains their higher 
binding affinity and stability. 
 
Table 3: A comparison of GSK952 binding affinity with that of top 2 hits ZINC54359621 and 
ZINC46849657 
Ligand ∆Total ∆EvdW ∆Eelec ∆Gbind ∆Ggas ∆Gsolv 
GSK952 -58.8 -61.2 -21.4  30.9 - 82.6 23.8                 
ZINC46849657 -58.5 -67.1 -21.0 37.1 -88.1 29.6 
ZINC54359621 -59.0 -67.6 -20.2 36.4 -87.9 28.8 
 
PRED of the top 2 hits showed consistency compared to that of GSK952. The residues that contributed to 
the binding of GSK952 to HIV-1 RT protein also contributed to the binding of the top two hits (Figure 





Figure 6: The per residue graphs A and B showing FBE contribution for both ZINC54359621 and 
ZINC46849657 respectively.  
It is noted that ZINC54359621 has a hydrogen bond between the oxygen atom of Pro236 and the NH 
group of the aromatic ring, NH group of Lys103 and the oxygen atom of the aromatic ring. 
ZINC46849657 has a hydrogen bond between the oxygen atom of Pro236 and the NH group of the 
aromatic ring, the NH group of residue Lys103 and the oxygen atom of the aromatic ring (Figure 7). 
These are one of the key interactions required for the binding to HIV-1 RT. This indicates the compounds 





Figure 7: Binding mode of compound a) ZINC54359621, and b) ZINC46849657 to HIV-1 RT enzyme 
respectively.  
HIV-1 RT is highly flexible in nature300,301 and therefore the stability of the system during MD simulation 
was analyzed by computing i) RMSD (S6A) and ii) RMSF (S6B). The average value of RMSD for 
ZINC54359621 and ZINC46849657 is 3.12 Å and 2.58 Å respectively. These RMSD values presented in 
S6 have proven to be similar with  the HIV-1 RT RMSD values presented in literature 302,303 thus, 
validating the stability of the system due to the high flexibility of HIV-RT protein. RMSF shows good 
stability of all residues interacting with the ligands from residues 100-236. The average RMSF for 
ZINC54359621 and ZINC4684965 are 1.87 Å and 1.53 Å respectively. Further, the compactness of the 




ZINC46849657 is 51.2 Å respectively. Results show that the target protein folded correctly and was able 






























Virtual Screening was carried out to identify the potential inhibitors against mutated HIV-1 RT based on 
(i) PRED-based pharmacophore model, (ii) molecular docking and (iii) MMPBSA approaches. The study 
identified two novel hits ZINC54359621 and ZINC46849657. These compounds may be representatives 
of a new series of NNRTIs possessing high resistance profiles against mutated HIV viruses. They have 
the potential to inhibit the transcription of the viral RNA by binding to the active site of the RT's p66 
subunit therefore the replication rate of the virus decreases. The pharmacophore approach was further 
refined, where the candidate molecules for structure-based VS were chosen based on their orientation and 
chemical features in relation to the 3D structure. The PRED was also calculated in order to obtain more 
insights into the crucial protein residues involved in ligand binding. This will potentially aid in the design 
of potent inhibitors that bind to these HCAAR. The results presented in this study present a map to the 
innovation and design of potent drug candidates against different biological targets. Results have shown 
that choosing highly contributing FBE candidates from a library of compounds generated from PRED 
target-bound pharmacophore map is a more reliable and accurate approach. 
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S1: Two key binding interactions exist between GSK952 and the backbone NH and C=O 
groups of Lys103 of HIV-1 RT. 
S2: PRED of HCAAR for GSK952. 
Residue 
number 
Highly interacting residues FBE (kcal/mol) 
1 Val106   -3.556 
2 Lys103   -3.311 
3 Tyr188   -3.144 
4 Lys102   -2.243 
5 Leu100   -2.057 


















Val106 -4.812 -4.342 -0.272 
Lys103 -2.446 -1.176 -2.933 
Tyr188 -2.919 -2.556 -1.459 
Leu100 -2.242 -1.995 -0.048 
Pro236 -1.986 -2.564 -0.093 
Phe227 -1.873 -2.147 -0.450 
Leu234 -1.906 -2.055  0.496 
Lys102 -1.795 -1.480 -1.461 
Tyr181 -1.488 -1.899 -0.277 











Val106 -4.754 -4.262 -0.312 
Lys103 -2.454 -1.058 -3.305 
Tyr188 -2.692 -2.494 -1.461 
Leu100 -1.876 -1.694 -0.023 
Pro236 -2.062 -2.679 0.041 
Phe227 -2.042 -2.287 -0.528 
Leu234 -1.845 -1.996 0.477 
Lys102 -1.865 -1.310 -1.660 
Tyr181 -1.397 -1.753 -0.277 












S6: MD Simulations results of ZINC54359621 and ZINC46849657 A) RMSD (Average of 3.12 
Ǻ and 2.58 Ǻ respectively), B) RMSF (average of 1.87 Ǻ and 1.53 Ǻ respectively) and C) Rg 
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Heat shock protein (Hsp) 90 is an emerging and attracting target in the anti-HIV drug discovery process 
due to this key role in the pathogenicity of HIV-1 virus. In this research study, long-range all-atom 
molecular dynamics (MD) simulations were carried out for both the bound and the unbound proteins to 
improve the understanding of the molecular mechanisms of the Hsp90 dimerization and inhibition. 
Results evidently show that coumermycin A1 (C-A1), a recently discovered Hsp90 inhibitor, binds at the 
dimer’s interface of Hsp90 and leads to a substantial parting between dimeric opposed residues, which 
include Arg591.B, Lys594.A, Ser663.A, Thr653.B, Ala665.A, Thr649.B, Leu646.B and Asn669A. 
Significant differences in the magnitudes were observed in the radius of gyration (Rg), root-mean-square 
deviation (RMSD) and root-mean-square fluctuation (RMSF), which confirms a reasonably more flexible 
state in the apo conformation associated with it dimerization. In contrast, the bound conformer of Hsp90 
showed less flexibility. This clearly highlights the importance of the inhibition process resulting from the 
binding of the ligand. These findings were further validated by Enhanced Molecular dynamics (EMD), 
also known as principal component analysis (PCA). We believe that the detailed dynamic analysis of 
Hsp90 presented in this study, would give an imperative insight and better understanding to the function 
and mechanisms of inhibition of Hsp90. Furthermore, information obtained from the binding mode of the 
inhibitor would also be of great assistance in the design of more potent inhibitors against the HIV target 
Hsp90. 




1. Introduction  
Acquired immunodeficiency syndrome (AIDS) is the most challenging disease outbreak thus far and is 
caused by the Human Immunodeficiency Virus (HIV)153. HIV/AIDS affected over 35 million people 
globally, and Sub-Saharan Africa is the most affected region with approximately 68% people affected304.  
Highly active antiretroviral therapy (HAART), approved by the Food and Drug Administration (FDA), is 
currently the most effective therapeutic regimen decreasing the viral load, which prolongs the survival of 
AID-free patients305,306. These drugs include inhibitors of three essential HIV enzymes protease, integrase 
(IN), reverse transcriptase (RT) as well as entry and progression enzyme inhibitors of in the HIV life 
cycle307,308. In spite of all currently existing anti-HIV therapies, resistant strains still poses a problem. This 
creates a demanding necessity for the identification of new antivirals that do not induce drug resistance. 
Hsp90 is an ATP-dependent chaperone  crucial for maintaining active forms of other proteins which are 
known as client proteins175. Hsp90 has also been reported to be responsible for the replication of nearly all 
kinds of viruses such as DNA, RNA viruses, and double-stranded RNA viruses309.  Hsp90 is a 
homodimeric protein comprising a dimeric molecular weight of 90kDa. Each monomer shares a common 
domain organization which consists of a C-terminal dimerization domain (CTD) of ~12 kDa, a middle 
domain (MD) of ~40 kDa and an N-terminal domain (NTD) of ~25 kDa, which is found mostly in almost 
every part of eukaryotic cells310–312.  Amongst other proteins, Hsp90 is one of the most profuse proteins 
found in the cytoplasm, where it makes up approximately 1–2% of the total protein levels313.  It is 
responsible for the controls of activities, such as the maturation, localization of a selected large number of 
substrates called “client proteins” in the cytoplasm.  These clients proteins are part of several processes 
including transcription, translation, mitochondrial function, kinetochore assembly, inflammation, 
immunology, cellular antiviral defense pathways, apoptosis, centrosome function and cell cycle314–316.  
Studies have demonstrated that the replication of viruses to be sensitive to Hsp90 inhibitors at very low 
concentrations without affecting cellular viability, due to their dependence in Hsp90 for their survival. 
Hsp90 is regarded as an essential protein for malignant transformation and progression, thus target protein 
for anti-cancer drugs317,318. A previous study in our laboratory gave a computational perspective of Hsp90 





Figure 1: Hsp90 x-ray crystal structures accentuating different domains. The surface representations were 
generated using PDB co-ordinates of 1BGQ (NTD+RD), 1YET (NTD+GA), 1HK7 (MTD) and 1SF8 
(CTD). 
Recent studies revealed that the C-terminal domain (CTD) of Hsp90 protein has a crucial role in the 
dimerization of the chaperones with an additional binding site for inhibitors.  It has also been reported that 
the nucleotide binding site situated at the CTD is more favorable to guanosine-5'-triphosphate (GTP) over 
ATP, which would possibly enhance the selectivity of the new inhibitors against this site321–323. Herein we 
focus on the C-terminal dimerization inhibitors because this domain is vital for the biological activity of 
Hsp90307. 
To date, a broad-spectrum of antivirals have been identified, including Hsp90 inhibitors309,324–326 . 
Numerous antiviral activity of Hsp90 inhibitors have been proved against tissue culture of ill health 
conditions such as picornaviruses poliovirus, coxsackievirus, rhinovirus, influenza virus, 
paramyxoviruses, Hepatitis C virus (HCV), Ebola virus, vesicular stomatitis virus, severe acquired 




vaccinia virus, and herpes viruses320,324,327–333. Gryase B inhibitors (novobiocin, coumermycin A1 (C-A1) 
and daunorubicin) have been reported to impair HIV-1 Replication the most, by targeting Hsp90320. It has 
been shown that they inhibit the formation Hsp90 dimer by binding in the C-terminal domain, which 
impairs viral gene expression320.  
The present study looked at C-A1, which has previously been screened for its antiretroviral activity by 
means of a chemical genetics (CG) approach320.  This study confirmed the impairment of viral gene 




Figure 2: The 2D structure of coumermycin A1. 
Molecular dynamic simulations and post-dynamics (PD) to be the closest methods to the actual wet lab 
experimentation and is of great help in the understanding of the complex biological phenomenas such as 
the binding mechanism of inhibitors to their target protein334. An application of continuous MD 
simulations to reveal folding and the unfolding activities of biological enzymes has made it convenient to 
fathom the dimerization process complexity of macromolecules 335–339. The increased application of the 
PD methods in computational chemistry validates the usefulness of this technique in understanding the 
conformational dynamics aspects of biological macromolecules. The most broadly improved PD 
methodologies used to search for structural dissimilarities within distinctive biological phenomenas 
include PCA or essential dynamics (ED) analysis307,340. Although PCA has proved it competency to be 
implement in the comparison of motions of different macromolecules there are additional techniques to 
PCA analysis which were also applied to comprehend the of the biological phenomena’s conformational 
behavior321,341. Such may include dynamic cross-correlation (DCC), which was valuable to gain insights 
on macromolecular motions in different biological systems342. To understand both the dimerization and 
the inhibition processes of Hsp90, virtual MD simulations were employed for the bound and the unbound 




computational insight on Hsp90 as a vital HIV target. Thus, we expect this study to significantly 
contribute towards an improved understanding of the Hsp90 protein structure, dynamics and its 
mechanism of inhibition. Herein, we presented the structural and dynamic insight that can be executed in 
the discovery of drugs and the development of more effective HIV inhibitors against Hsp90. 
2. Computational methodologies 
2.1. System Preparation 
There is no available crystal structure of the human C-terminal portion of Hsp90, however structures of 
yeast (2CG9)343 and E. coli (1SF8)344 Hsp90 orthologues are available.  2CG9 was chosen for this study 
due to the fact there is very high sequence and structural conservation among Hsp90 proteins from 
prokaryotes to Homo sapiens 167. The ligand and protein systems were prepared in the similar manner as 
mentioned in the previous reports345,346. Auto-Dock Vina248 was used to generate docked conformation of 
C-A1 inside Hsp90’s active site using a previously reported procedure320.  
2.2 Molecular dynamic simulations 
The unbound and C-A1 bound models of Hsp90 proteins were exposed to all-atom, continuous MD 
simulations in precise solvent using the GPU version PMEMD engine integrated with Amber14284. The 
ff99sb force field286 applied with Amber14 was employed in the description of the protein systems.  To 
neutralize the system, missing hydrogen atoms and counter ions were added using the Leap module, 
integrated with Amber14.  All the systems were submerged into an orthorhombic box with TIP3P347 water 
molecules in a manner that none of the protein atoms were contained in 12 Å of any box edge prior to the 
set up. The Particle mesh Ewald (PME)288 technique was employed to calculate the continuous 
electrostatic interactions and van de Waals cut-off of 12 Å.  Initial minimization was implemented for 
50000000 steps of steepest descent using conjugate gradients algorithm.  CPU version of Amber 14 was 
used to perform all the minimization but before the minimization step, a gradual heating from 0 to 300 K 
by means of Langevin thermostat289 with a collision frequency of 1/ps using an official ensemble (NVT) 
was used. All systems were successively equilibrated at 300k in a NPT ensemble for 100000 ps with no 
restrained and to uphold the pressure at 1 bar Berendsen barostat291 was used. To restrict the bonds of all 
covalently bonded atoms to hydrogen atoms for all MD simulations runs the SHAKE algorithm290 was 
used. The MD was run continuously in a NPT ensemble for 100 ns with a target pressure of 1 bar and a 
pressure-coupling constant of 2 ps. In every 1 ps the trajectories were examined and more analyses 
namely RMSD, RMSF, Rg, inter atomic distances, DCC and PCA were performed using PTRAJ and 
CPPTRAJ modules integrated in Amber14. All plots and visualization were performed in Chimera 





2.3 Free binding energy calculations. 
The docked complex of Hsp90-C-A1 was calculated to predict the binding efficiencies and confirm the 
highly contributing amino acid residues (HCAAR) of C-A1 binding to Hsp90. The binding affinity 
predictions were executed using the MMPBSA with equation (1)295 and MMGBSA method that with 
equation (2)348. 
   ∆Gbind = Gcomplex- Gprotein- Gligand            (1) 
                =  ∆EMM + ∆GPB+ ∆Gnon-polar - TΔS 
 
     ∆Gbind = ∆EMM + ∆Gsolv + ∆GSA      (2) 
  
Where, ΔEMM is the differentiation between the minimized energies of the Hsp90-C-A1 complex and the 
total energies of the Hsp90 and Hsp90 inhibitor including the electrostatic and the van der Waals 
energies. The change in entropy of the ligand binding conformations is presented by TΔS, the variance in 
the P/GBSA solvation energies of the Hsp90-C-A1 complex and the summation of the solvation energies 
of the Hsp90 and Hsp90 inhibitor is represented by ΔGsolv and ΔGSA is the difference in the surface area 
energies for the Hsp90 and Hsp90 inhibitor. Both MMPBSA and MMGBSA methods have been 
recognized to ensure the inhibitors are ranked accurately in accordance with their binding energy and thus 
can aid as a potent tool in the drug design research. 
2.4 Principle Component Analysis (PCA) 
Principle component analysis (PCA) is extensively used to effortlessly examine and identify data 
generated from MD simulations to highpoint principal modes accountable for changes in conformation307. 
The PTRAJ and CPPTRAJ modules were used in performing PCA C-alpha atoms349 integrated with 
Amber 14284. The plots analysis showing the central conformational motions descriptive of each structure 
were created using Origin data analyses programme (www.originlab.com).  
2.5 Dynamic cross correlation matrix 
The DCCM between fluctuations based on the residues throughout the simulation was analyzed using the 





                                         
             DCCM(I, j) =
<∆𝑟𝑖(𝑡)∙∆𝑟𝑗(𝑡)>𝑡
√<‖∆r𝑖(𝑡)‖2>𝑡 √<∆𝑟𝑗(𝑡)2>t 
                   (3) 
                                                                                                        
Where ri(t) defines the vector of the atom’s coordinates as a function of time t, <⋅> 𝑡 measures the time 
ensemble average and Δri (t) = ri(t)˗˂ri(t)˃t . The backbone Cα atomic fluctuations were considered during 
the DCCM analysis. 
3. Results and Discussion 
3.1. Insights into coumermycin A1 bound with Hsp90 
The lig-plot351 analysis is best suited for displaying the 2D interaction between the ligand and the amino 
acid residue contributing to the ligand binding to the receptor. The structure of inhibitor C-A1 docked 
within the Hsp90 dimer’s binding site gave essential evidence on the binding of the ligand inside the 
active site (S1). It was observed that C-A1 formed hydrogen bonds interactions with Arg591.B, 
Ala595.A, Glu660.A, Lys480.B, Ser663.A and Ser666.A (S1) residues of both Hsp90 dimer subunits. 
Interestingly, the binding of C-A1 is at the dimer of Hsp90 possessing multiple common residues from 
both sub-unit A and B in its active site. The averaged values of the calculated free energy, using 
MM/PBSA approach; over the 100 ns MD simulations for each CAAR to the binding of C-A1 to Hsp90 
are illustrated in Figure 8, S3. The CAAR formed hydrogen bond interactions, which is one of the key 
interactions favorable and vital for binding of a ligand to its receptor, possess higher binding affinities.  
The plot of the interaction (Figure 3) high spots the C-A1 location within the Hsp90 dimer and reciprocal 






Figure 3: The binding mode of C-A1 to Hsp90 subunits. 
The existence of hydrophobic/aromatic interactions, which promotes the appropriate binding of inhibitor 
into the dimer, consisting of key active site residues involved in dimer packing, including Ser595.A and 
Glu660.A, are visibly illustrated in the binding mode.  It is assumed that binding of C-A1 in the Hsp90 
dimer’s active site results to the dimer inhibition of Hsp90. The dynamic insights of the dimerization 
mechanism process of Hsp90 through inhibition by C-A1 was obtained from the continuous MD 
simulations using the structure of Hsp90-C-A1 complex (docked) (S2). 
3.2. Molecular dynamics simulations and Post-dynamics Analysis 
3.2.1. RMSD, RMSF, and Rg. 
Protein dynamics, structure, and function are highly interrelated. The conformational changes of Hsp90 
are particularly critical for enzyme function164,352. Studying internal atomistic motions can unravel the 
dynamics nature of Hsp90, which is responsible for numerous biological functions as enzymes. Molecular 
dynamic simulations were performed for each enzyme (apo and bound) to establish the drug-binding 
pattern and to better understand the interaction of C-A1 with the CTD, to ensure the stability of the MD 
trajectories dynamic and the stabilities dissimilarities of MD simulations. The values of the RMSD for the 
protein backbone atoms and side chain atoms in relation to the initial minimized structure throughout the 





Figure 4:  The (RMSD) values for the dimer atoms during continuous 100 ns MD simulation. 
The average structure for the complete simulation was measured by calculating values for all residues of 
both in Apo and bound conformations (Figure 5) by means of the RMSF in order to obtain the system’s 
subset movement. Residues between 400 to 600 have the highest RMSF values, this corresponds to CTD. 
The most stable areas are the areas with the lowest RMSF values. Overall the bound enzyme has slightly 
lower RMSF values of 1.88 Å compared to the apo with the value of 2.64 Å, which indicates that the 






Figure 5: C-α atom RMSF values given for each residue number in both systems. 
The mass-weighted root mean square distance of a collection of atoms from their common center of mass 
best describes the Rg. To measure for the compactness of a structure, the Rg was calculated. The analysis 
shown in Figure 6, S5 provides us with an understanding into the dimensions of the dimeric cleavage and 
of the overall Hsp90 protein respectively. We observed the major fluctuations in both systems between 0 
and 100000 ps. The Rg indicated higher structural deviations for the apo conformation in comparison to 
the bound conformation. The mean value of the bound is lower than that of the apo, which indicates that 





Figure 6: The radius of gyration (Rg) of the dimeric subunit during 100 ns MD simulation.  
3.2.2. Principal Component Analysis 
The trajectories’ projection obtained at 300 K onto the first two principal components (PC1, PC2) 
presented the motion of two proteins in phase space. Clusters were better defined in the bound 
conformation than the apo conformation. Furthermore, the bound conformation covered a larger region of 






Figure 7: PCA projection of C-α atoms motion constructed by plotting the initial two principal 
components (PC1 and PC2) in conformational subspace. 
3.2.3. Per-residue energy decomposition (PRED) 
In an effort to offer more insight into the involvement of each amino acid residue toward the binding of 
C-A1, PRED was computed for the system.  This helps us to observe the residues with the most 
contribution to the ligand binding, as seen from Figure 8 the residues from both monomers showed 
interaction favorable to the ligand via different interactions. This further advocates that C-A1 inhibit 
dimerization. This information will ideally assist medicinal chemists in the design of inhibitors that 






Figure 8: Graph showing binding energy (Total), van der Waals (vdW), polar solvation (PS) and non-
polar solvation (NPS) contribution for each HCAAR.  
 
3.2.3 Dynamic cross correlation  
The DCCM is shown in Figure 9, S7, which has been calculated for both bound and unbound 
conformations of Hsp90 dimer subunits and Hsp90 as a whole. The free state of Hsp90 displayed a more 
correlated motion, which further justifies the occurrence of the dimerization process resulting in a more 
correlated residue-residue interaction. The bound state, on the contrary, showed a much greater reduction 
in correlated motions during simulations. With these findings we can thus conclude that C-A1 inhibited 
the dimerization mechanism of Hsp90. The suitability of C-A1 to inhibit dimerization mechanism is 






Figure 9: DCC matrix of the dimeric subunit during simulation taking into consideration C-α residues of 
Hsp90 ligand -bound (A) and free (B) conformations. 
The distance between the dimer residues in each dimeric subunit were calculated by measuring the 
interatomic distances between the Cα atoms along the simulations to gain an in-depth insight of dynamics 
of the dimerization process. Figure 10, S3 highlights these residues.  
 





The distances between the orthogonal residues for the apo conformation were comparatively higher than 
that of the bound conformation as the average Cα distances specified on Table 1, S6.  The standard 
deviation of distances for the apo conformation was higher than that of the bound conformation, 
indicating that the latter enzyme is more stable (agreeing with the RMSF, Rg and PCA studies).   
Table 1. Residues involved in dimer packing and their averaged distances from each other throughout 
simulation. 
Residues Apo/Å Bound/ Å 
S663A-T653B 8.54 ± 0.40 8.46  ± 0.35 
A665A-T649B 6.43 ± 0.57 5.55  ± 0.38 
N669A-L646B 9.88 ± 0.72 7.32  ± 0.50 
K594A-R591B 13.11 ± 0.91 12.44 ± 0.50 
 
These substantial dissimilarities in distances between residues in the arranging of the dimer guaranteed 
the inhibitions of Hsp90 by C-A1 through the formation of a stable interaction with residues involved in 
the dimerization, preventing the dimer from opening and allowing the substrate from entering.  This fact 
further correlates with previous biochemical analyses aimed at mapping the binding site of C-A1 in 
Hsp90 suggesting that the viral gene expression inhibited by C-A1 through the interference with Hsp90 
dimerization320.  
 
Figure 11: Snapshots of unbound and C-A1-bound conformations of Hsp90 at a definite frames during 




Snapshots for the MD simulations for both the apo and the C-A1-bound conformations of Hsp90 were 
taken at specific time interval corresponding to the distances of orthogonal residues (S6) where it is 
evident for both conformations opening and closing. This further substantiate the lack of dimerization in 






























Molecular dynamic simulations revealed differences in the dimerization mechanism of Hsp90 in its 
unbound and C-A1-bound conformations. Micro-molecule inhibitors such as C-A1 prevent the 
dimerization process by targeting the dimer of Hsp90. We believe a more conformational rigid system 
was due a dimerization process being delayed. This was indicated after the analysis of the RMSF and Rg 
proving a more conformational supple nature of unbound Hsp90, whereas the C-A1-bound conformation 
of Hsp90 was found to be more stable with a declined dimerization throughout the MD simulation. The 
binding of C-A1 to the Hsp90 dimer subunits inhibits the process of dimerization. This is further 
validated by observing the distance between the residues that are involved in the dimerization process. 
This is the first report emphasizing the important computational insight of the features of a crucial HIV 
target, which would also serve as an appropriate foundation in the process of designing new compounds 
against Hsp90 as future anti-HIV drugs.  
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S1: Residue interaction lig-plot of C-A1 inside the active site of Hsp90. Hydrogen bond and 




























Glu592 -1.136 -2.188 1.331 -0.279 
Ser595 -1.626 -2.504 1.175 -0.297 
Ser598 -1.461 -0.772 1.367 -0.347 
Glu1040 -1.858 -3.124 1.651 -0.385 
Ser1041 -1.275 -1.810 0.768 -0.232 
Ala1044 -1.873 -2.154 0.484 -0.203 
Lys1047 -1.519 -3.218 2.210 -0.512 














































S6: Distances between residues involving (A) Ser663 and Thr653 (B) Ala665 and Thr649 (C) 




















S7:  Dynamic cross correlation map of Hsp90-bound (A) and free (B) during simulation run of 







6.1 General conclusions and recommendations for future studies 
  
A general conclusion of the study as well as recommendations for future research based on its findings 
will be outlined in this chapter.  
6.1.1. General Conclusions 
The reported research study reported herein is comprised of two aims: (i) To improve and refine the 
current pharmacophore approach, which will search for compounds that interact with the highly 
contributing residues based on the FBE for the HIV-1RT inhibition (ii) To study the mechanism of 
inhibition of Hsp90 dimerization by Gyrase B inhibitor C-A1. The aims of the studies were 
consummately accomplished and the results obtained from this work generated the listed conclusions 
below: 
1) In this study the pharmacophore-based VS was used to screen for more potent HIV-1 RT 
inhibitors. This was an energy-based pharmacophore map, which was generated using the FBE 
calculated from MD. This approach was intended to unfetter the conventional pharmacophore 
approaches limitations. The compounds screened using this model were docked against HIV-1 
RT. The docking method was successfully validated using known HIV-1 RT inhibitors and a 
reasonable R2 value of 0, 62128 was obtained. Post to docking, MD simulation and MMPBSA 
were calculated for the top 10 compounds and two compounds showed a greater binding affinity 
compared to the prototype compound reported in literature150. Post-dynamic analysis proved our 
system to be stable throughout MD simulations. 
2)  This was a conformational study to investigate the C-A1 (Gyrase B inhibitor previously 
experimentally investigated320) mechanism of inhibition when bound to the CTD of Hsp90 
protein (an emerging anti-HIV target). A continuous MD production, for both the bound and the 
unbound conformations, was run for 100ns and the post-dynamic analysis were carried out for 
both systems. The results were plotted using origin data analysis software353.  
3) The post-dynamic analysis such as RMSD, RMSF, Rg, PCA, inter atomic distances and DCC 
plots showed significant differences for both systems. The residue of the unbound conformation 
according to RMSF showed higher fluctuation in amino acid residues in the region of 400 to 600 





4) It is also evident from RMSD that both the systems were equilibrated (not exceeding 2Å) towards 
the end of the simulation of 100 ns. The systems for bound and unbound conformations reached 
their stability after 60000 ps and 80000 ps respectively. 
5) Results have shown that choosing highly contributing FBE candidates from a library of 
compounds generated from PRED target-bound pharmacophore map is a more reliable and 
accurate approach for the first study and the binding of C-A1 to the Hsp90 dimer subunits inhibits 
the process of dimerization for the second study. It can be concluded from the results obtained 
from both studies that the computational evidence from these present studies would serve as an 
appropriate foundation in the process of designing new compounds against both HIV-1 RT and 
Hsp90 as future anti-HIV drugs. 
The results presented in these research studies shows us how promising these computational approaches 
and methods are for the discovery and development of drugs. They will eventually contribute to enhanced 
diagnosis and escalation of the rates of survival of HIV-1-infected patients. This is evident from previous 
successful computational studies on the HIV targets354–359. 
6.2. Recommendations and Future Studies 
The computational chemistry methods employed in this study including VS, MD simulation, FBE 
calculation using MM/GBSA method (integrated in AMBER 14) and the post-dynamic analyses offer an 
inexpensive yet powerful tool for the design and drug discovery. These methods were involved in the 
inhibitory mechanism of compounds in the active site, determination of energy interactions of active site 
residues towards ligand binding and the authentication of results from docking studies. 
6.3. The following may be included in the future studies: 
1. To further validate the novel inhibitors, screened using an improved pharmacophore based VS 
approach, using an experimental approach. 
2. Use the improved pharmacophore based VS approach to screen for more Hsp90 inhibitors using 
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